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ABSTRACT 
 
Sean Christopher Barron: Molecular Mechanisms of Allosteric Modulation of 
Nicotinic Acetylcholine Receptors 
(under the direction of Dr. Robert L. Rosenberg) 
 
 Nicotinic acetylcholine receptors (nAChR) are part of the Cys-loop family of 
ligand-gated ion channels, and are implicated in a wide variety of neurological 
disorders such as nicotine addiction, schizophrenia, and cognitive dysfunction. 
Therefore, they represent a critical molecular target for drug development and 
targeted therapeutic intervention. Positive allosteric modulators (PAMs) of ligand-
gated ion channels have a unique therapeutic potential because they enhance 
synaptic transmission without disrupting the endogenous timing mechanisms. This 
research focused on the neuronal α7 nicotinic receptor because they are located 
both pre- and postsynaptically and can modulate glutamatergic and dopaminergic 
release in the brain regions involved in drug-seeking behaviors.  Understanding the 
molecular mechanisms by which allosteric modulators enhance activation of 
neuronal nicotinic acetylcholine receptors is therefore critically important to the 
development of new drugs for research and therapeutics.  
 Experiments with the Substituted Cysteine Accessibility Method indicate that 
two chemically different positive allosteric modulators, PNU-120596 and permeable 
divalent cations, cause structural transitions (or changes in local electrostatic 
potential) in the extracellular ligand binding domain of the α7 nicotinic receptor that 
 iv 
are similar but not identical to those caused by the agonist, acetylcholine. These 
results suggest that positive allosteric modulators share a conserved mechanism to 
enhance receptor gating that is unrelated to the chemical structure of the molecule. 
 As an additional approach to study gating of the nicotinic receptors, I 
developed homology models derived from the structures of bacterial Cys-loop 
receptors in the closed and open states. A comparison of electrophysiological 
MTSEA modification data against in silico calculations of solvent accessibility and 
electrostatic potential showed that electrostatic potential in the extracellular ligand-
binding domain of the α7 nAChR is a better predictor of receptor gating from the 
closed to open states.  
 Overall, this body of work has shown that positive allosteric modulators and 
agonists of the α7 nAChR induce similar conformational changes in the extracellular-
ligand binding domain of the receptor by reducing the large electronegative potential 
energy along the ion-permeation pathway. A unifying model of receptor gating 
(electrostatic compensation) and future experiments designed to test this model are 
discussed.  
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INTRODUCTION 
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 Nicotinic acetylcholine receptors are the prototypical member of the Cys-loop 
family of ligand-gated ion channels, which also includes GABAA, serotonin type 3 (5-
HT3), and glycine receptors. These ligands bind to their respective ionotropic 
receptor, inducing a conformational change in the receptor that allows for ion 
permeation through the channel.  Seventeen genes encoding for different nAChR 
subunits have been identified and classified into the alpha subfamily (α1-α10), beta 
subfamily (β1-β4), and muscle-specific (γ, δ, ε) subfamily [Gotti et al. 2007]. As a 
family, the nAChRs share a conserved molecular architecture with other Cys-loop 
ionotropic receptors and assemble as heteromeric or homomeric pentamers around 
a central pore within the plasma membrane [Raftery et al. 1980; Anand et al. 1991].  
In vertebrates, nAChRs are cation-selective channels (Na+/K+) with variation 
in Ca2+ permeability among different subtypes. Nicotinic acetylcholine receptors 
have a complex stoichiometry of assembly that influences the pharmacology and 
biophysical properties of the assembled receptors, and they are divided into three 
broad categories. Alpha-bungarotoxin-sensitive (α-Bgtx) nAChRs consist of 
homomeric α7 receptors and α8, α9, and α10-containing receptors. The α7 
receptors have nanomolar affinity for the competitive inhibitor α-Bgtx, micromolar 
affinity for nicotine, rapidly desensitize, and are highly permeable to Ca2+ [Couturier 
et al. 1990; Mulle et al. 1992]. Muscle nAChRs consist of (α1)2β1δγ/ε subunits, 
have low but significant permeability to calcium, and bind irreversibly to α-Bgtx 
[Leprince et al. 1981; Vernino et al. 1994]. Non-α-Bgtx nAChRs consist of any 
combination of the other heteromeric, neuronal nAChRs (α2-α6, β2-β4). These 
receptors do not bind α-Bgtx, have nanomolar affinity for nicotine, slowly desensitize, 
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and are relatively impermeable to Ca2+ [Vernino et al. 1992; Fucile 2004; Gotti and 
Clementi 2004]. All nAChRs show strong inward rectification at positive membrane 
potentials due to intracellular block of the receptor by Mg2+ [Ifune and Steinbach 
1990; Ifune and Steinbach 1991; Briggs et al. 1995; Wu et al. 2006].   
 
nAChR pharmacology  
  The pharmacological properties of the nicotinic acetylcholine receptors have 
been extensively characterized, due to the large variety of agonists, competitive and 
non-competitive antagonists that occur naturally.  Historically, the classification of 
receptor subtype was determined by pharmacology before the individual genes were 
identified and cloned.  
 The history of acetylcholine and its significance in neurotransmission dates 
back to the past century.  Sir Henry Dale isolated and determined the structure of 
acetylcholine in the early 1900’s. By the early 1920’s, Otto Loewi had discovered 
that acetylcholine and epinephrine acted as chemical messengers of the nervous 
system, which we now define as a “neurotransmitter.” Both compounds were found 
to be secreted from the vagus nerve after electrical stimulation, and Dale and Loewi 
shared the Nobel Prize in Physiology or Medicine for their pioneering work. 
Additionally, Sir Henry Dale first determined the two classes of acetylcholine 
receptors, based on the differential response of cells to nicotine and muscarine [Dale 
1914; Dale 1954]. We now know that nicotinic acetylcholine receptors are ligand-
gated ion channels that mediate fast neurotransmission, while muscarinic 
acetylcholine receptors mediate slow neurotransmission via G-protein coupled 
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receptors [Daly 2005]. This body of work focuses on the nicotinic acetylcholine 
receptors. 
 Pyridine alkaloid agonists, such as (-)-nicotine, (-)-nornicotine, and anabasine 
(Figure 1.1), are found in the leaves of tobacco plants (genus Nicotinana) and are 
presumed to act as herbivore deterrents at non-toxic doses [Metcalf 1992; 
Glendinning and Gonzalez 1995]. Analogously, the potent agonist epibatidine and a 
wide variety of alkaloid non-competitive antagonists are secreted on the skin of 
phantasmal poison frog (Epipedobates tricolor) as a predatory deterrent [Daly 1995; 
Daly 2005].  The potent competitive antagonist, (+)-tubocurarine, is the main 
component of the poison curare used by South American tribes to paralyze the 
respiratory muscles of prey [Wintersteiner and Dutcher 1943]. Finally, predatory 
animals utilize nicotinic receptor peptide antagonists as paralytics, such as α-
bungarotoxin from the Taiwanese Banded Krait (Bungarus multicinctus) or the α-
conotoxins from the marine cone snails (genus Conus) [Nicke et al. 2004; Chu 
2005].  
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 Figure 1.1: Agonists and antagonists of the nAChR.   Unless otherwise stated, the 
numbers underneath each compound are the equilibrium dissociation constant (Ki, in nM) and are 
from [Daly 2005]. Only the physiologically relevant enantiomers are shown where applicable, and Ki 
values are reported in the same order: α4β2/α3β4/α7/α1(2)β1γδ. A smaller value corresponds to a 
higher binding affinity and higher specificity for that nAChR isoform with the exception of GTS-21, 
which has a higher affinity for α4β2* but the primary effect is full agonism of α7 receptors. Relative 
selectivity is shown for ABT-418. “*” denotes partial agonism is the primary effect for those 
compounds (cytisine and varenicline at α4β2* receptors), and “–“ denotes no measurable binding or 
effect at that nAChR isoform. All compounds occur naturally except varenicline, ABT-418, and GTS-
21. [Arias 1998; Lioudyno et al. 2000; Mihalak et al. 2006] 
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 The naturally occurring, small molecule drugs that target nicotinic 
acetylcholine receptors have served as templates for structure-activity relationships, 
in order to discover subunit-selective compounds (α7 vs. α4β2*, etc.)1 for research 
and clinical applications (Figure 1.1). It is important to note that selectivity of an 
agonist, antagonist, or allosteric modulator can be defined in multiple ways including 
binding affinity (Ki) or potency (EC50/IC50) using in vitro electrophysiological or 
calcium flux assays. An extensive review of the important natural compounds and 
their synthetic derivatives can be found elsewhere using Ki as a basis for 
comparison [Daly 2005].   From the structures and binding affinities of these 
compounds, we observe that the α4β2* receptors generally have a higher affinity 
and selectivity for agonists than both the α7 and α1(2)β1γδ isoforms. Nicotine, 
cytisine, morphine, and anabasine have served as important structural templates for 
the development of selective agonists of the α4β2* and α7 receptors. ABT-418 
(α4β2* agonist) and GTS-21 (α7
 
agonist) are representative compounds from this 
group. GTS-21 is unique because it acts as a competitive antagonist at α4β2* 
isoforms, but is a full agonist at the α7 isoform [Briggs et al. 1995; de Fiebre et al. 
1995; Briggs et al. 1997]. Therefore, this anabaseine derivative may serve as a 
useful template for additional α7-selective agonists. The most successful compound 
of this group is varenicline (Chantix©), which a partial agonist of  α4β2* receptors and 
full agonist of the α7 receptors and is FDA-approved for smoking cessation [Mihalak 
et al. 2006]. Selective competitive antagonists, such as dihydro-β-erythoidine 
                                                 
1
 For heteromeric nicotinic receptors, an asterisk is used refer to all possible subunit combinations and is a 
standard naming convention [Gotti et al. 2009]. For example, α4β2 nicotinic receptors can exist as either low 
affinity {(α4)3(β2)2}or high affinity {(α4)2(β2)3} for nicotine and acetycholine [Zwart and Vijverberg 1998; 
Nelson et al. 2003].  
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(α4β2*) and methyllycaconitine (α7), are important tools to determine agonist-
selectivity between neuronal nicotinic receptors.  
 The development of positive allosteric modulators for the nicotinic receptors 
has been based on a variety of chemical templates (Figure 1.2). Ivermectin was the 
first generation positive allosteric modulator of the homomeric α7 receptor [Krause et 
al. 1998], and is characterized as a macrocyclic lactone and an anti-parasitic 
compound that activates invertebrate glutamate-gated chloride channels [McCavera 
et al. 2007]. Ivermectin is also an allosteric modulator of the P2X4 receptor [Khakh 
et al. 1999], and an agonist of γ2-GABAA receptors [Adelsberger et al. 2000; 
Dawson et al. 2000]. Other important, but less selective modulators of the α7 
receptor include 5-hydroxyindole and genistein [Bertrand and Gopalakrishnan 2007]. 
The first breakthrough came with the discovery of PNU-120596 as the first selective 
α7 receptor positive allosteric modulator. This compound was developed from a 
urea/carbamide chemical library and exerts dramatic effects on macroscopic 
desensitization [Hurst et al. 2005; Piotrowski DW 2005]. Positive allosteric 
modulators that slow macroscopic kinetics and receptor desensitization are 
classified as type II [Gronlien et al. 2007]. In contrast, NS 1738 is also derived from a 
urea/carbamide library but does not exert any effect on macroscopic kinetics 
[Timmermann et al. 2007]. These modulators are classified as type I [Gronlien et al. 
2007]. Chemotypes that have been associated with GABAAR  modulators and 5-
HT2CR antagonists have been shown to enhance function of the α7 nicotinic receptor 
[Ng et al. 2007; Dunlop et al. 2008]. Finally, while most of the existing positive 
allosteric modulators are selective for homomeric α7 receptors, indolic alkaloids 
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have recently described as a chemotype selective for α4β2* receptors [Kim et al. 
2007].  
 
Figure 1.2: Allosteric Modulators of the α7 nicotinic receptor.  
Structures and differential profiles of PAMs at the α7 nAChR. Structures of prototypical positive 
allosteric modulators of nAChRs and their effects at α7 nAChRs measured in Xenopus oocytes or in a 
cell lines. Note the difference in time course of the agonist-evoked currents observed following 
exposure to type I or type II modulators. Data for NS-1738 and TQS adapted from [Timmermann et 
al. 2007]and [Gronlien et al. 2007] respectively. For details of allosteric modulator profiles of 
compound 6, galantamine and LY-2087101, please see cited references. Figure and text adapted 
from [Bertrand and Gopalakrishnan 2007]. [Broad et al. 2006; Lopes et al. 2007; Ng et al. 2007]
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Cholinergic neurotransmission  
 The development of selective compounds and existence of natural 
compounds that target the nicotinic receptors has been critical elucidating the 
mechanisms of nicotinic cholinergic neurotransmission. In particular, the peripheral 
nervous system and neuromuscular junction have been important models to study 
the basic properties of fast synaptic neurotransmission.  Pioneering work by Hodgkin 
and Huxley utilized the giant squid axon and determined that NaV and KV channels 
underlie action potentials [Hodgkin and Huxley 1952d; Hodgkin and Huxley 1952c; 
Hodgkin and Huxley 1952b; Hodgkin and Huxley 1952a; Hodgkin et al. 1952]. 
Shortly thereafter, Del Castillo and Katz utilized the neuromuscular junction and 
characterized the quantal nature of neurotransmitter release [Del Castillo and Katz 
1954].   
 Neuronal nAChRs (α2-α10 and β2-β4) are diffusely expressed throughout 
most of the central nervous system (CNS), with α4β2* and α7 receptors showing the 
highest levels of expression in experiments of radioligand binding to brain slices 
[Orr-Urtreger et al. 1997; Perry et al. 2002; Gotti and Clementi 2004]. In the 
peripheral nervous system, α3β4-containing and α7 receptors predominate in 
autonomic ganglion cells and  (α1)2β1δγ/ε receptors are expressed exclusively at the 
neuromuscular junction.  
 In the CNS, the cholinergic system has a unique architecture compared to the 
excitatory glutamatergic neurotransmission of the somato-cortical system. The 
somatosensory system is characterized by a columnar/modular organization and 
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bidirectional flow of information between the sensory cortices (feedforward), higher 
cognitive processing centers (feedback), and motor output regions along dedicated 
circuits [Gilbert and Sigman 2007]. In contrast, the cholinergic neurons show a large 
amount of interconnection at distal dendrites, receive sparse inputs that sample 
every cortical area, and form reentrant circuits between different brain regins [Woolf 
1991]. This diffuse yet interconnected architecture allows the cholinergic system to 
sample the internal state of the brain, and modulate both feedback and feedforward 
processes to effect behavior and cognition. The complex spatiotemportal integration 
of sensory information depends on the internal state of the system, which can be 
behaviorally defined as “attention.”  At the molecular level, the internal state depends 
on the combination and strength of excitatory and inhibitory input any individual 
neuron receives over time [Buonomano and Maass 2009].  
 While cholinergic neurons regulate the sensory-cortical network, nicotinic 
receptors are expressed on cholinergic and non-cholinergic terminals and can 
directly modulate other neurotransmitter systems  [Dani 2001]. For example, 
nicotinic receptors have been shown to modulate glutamate, GABA and 
norepinephrine release in the hippocampus, and glutamate release in the medial 
habenula [Radcliffe et al. 1999; Girod and Role 2001; Azam and McIntosh 2006]. 
Many other drugs of abuse including ethanol, cocaine, and PCP antagonize multiple 
nAChR subtypes [Arias 1998; Dopico and Lovinger 2009]. Nicotinic AChRs also 
affect cocaine-induced dopamine release in the ventral tegmental area (VTA). The 
VTA projects to the nucleus accumbens that ultimately leads to motor output, and so 
nAChRs can modulate the pathways that are important in drug addiction and drug-
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seeking behavior [Zanetti et al. 2007]. The α4β2* and α7 subtypes are implicated in 
a wide variety of neurological diseases such as nicotine addiction, schizophrenia, 
autism spectrum disorders, ADHD, Parkinson’s disease, epilepsy, depression, and 
anxiety disorders. [Fryer and Lukas 1999a; Fryer and Lukas 1999b; Rezvani and 
Levin 2001; Gotti and Clementi 2004; Hajos et al. 2005; Rabenstein et al. 2006; 
Mineur and Picciotto 2008]. The α7 receptor is also required to inhibit TNF release 
from macrophages, indicating its importance in non-neuronal systems as well [Wang 
et al. 2003].  
 The interconnectivity of the cholinergic system with multiple brain regions 
combined with the broad expression of multiple nAChR subtypes provides a 
framework for understanding the role of the cholinergic system in neurological 
diseases  and the promise of nicotinic receptor compounds as a therapeutic option 
for treatment. In order to understand how different nAChR subtypes contribute to 
disease states, it is critical to understand the molecular mechanisms by which these 
receptors couple the binding of agonists and positive allosteric modulators to 
opening of the channel. 
 
Structural models of nAChRs  
 Most of our working knowledge of the agonist-binding site of the Cys-loop 
receptor family comes from the work Brejc et al. [Brejc et al. 2001] and Hansen et al. 
[Hansen et al. 2005], who have solved the crystal structure of the Acetylcholine 
Binding Protein from Lymnaea stagnalis and Aplysia californica, respectively. The 
AChBP is a glial protein that is unique to several species of mollusks and other 
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invertebrates, and is secreted into the synaptic cleft to bind acetylcholine and 
sequester it away from the post-synaptic receptors [Smit et al. 2001]. These high-
resolution structures of AChBPs have been used to model the ligand-binding domain 
of the nAChRs because they provide a structural rationalization for decades of 
biochemical and binding studies. For example, the structure shows well-defined 
agonist binding sites that are lined by the residues previously shown to be essential 
for ligand binding. It also explains the requirement for at least two subunits because 
the binding sites are formed at the interfaces between subunits [Sine and Engel 
2006]. With this high-resolution structure, Unwin has refined his cryo-EM images of 
the Torpedo marmorata muscle-type nAChR down to a 4Å resolution to provide the 
first structural model of a full-length nAChR [Brejc et al. 2001; Unwin 2005]. More 
recently, high resolution and full-length de novo structures have been solved of 
bacterial Cys-loop receptors in the closed and open states [Chen 2009].  
 There are four major structural regions of the Cys-loop receptor family: the 
extracellular ligand-binding domain (LBD), the transition zone (TZ), the 
transmembrane domain (TMD), and the intracellular domain (ICD) (Figure 1.3) 
[Brejc et al. 2001; Unwin 2005].  In the LBD, the major structural feature consists of 
two arrays of β-sheets oriented in a β-sandwich. The agonist-binding site exists at 
the interface between two subunits in a pocket of aromatic and hydrophobic 
residues. The agonist binding site contains a C-loop that defines the principal 
subunit of the interface and moves to cover the bound agonist, acting as a cap or 
cover or the agonist-binding site. At the agonist-binding site, the C-loop is always 
part of an α subunit in full-length receptors. [Celie et al. 2005; Gao et al. 2005; 
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Hansen et al. 2005]. The C-loop of nicotinic receptors also contains aromatic 
residues and two cysteine residues that are important for agonist binding. The other 
subunit that contributes to agonist binding is called the complimentary subunit, and 
can be either an α or non-α (β, γ/ε, δ) subunit. The TMD consists of four α-helices; 
the M2 helix lines the pore of the channel [Oblatt-Montal et al. 1993; Akabas et al. 
1994; Unwin 2005], and the other helices (M1, M3, and M4) come into contact with 
the plasma membrane  [Barrantes 2002]. The TZ is composed of loops from the 
LBD and the TMD that serve to link these structurally different regions. Finally, the 
ICD is a partial α-helical structure linking the M3 and M4 helices. The ICD is involved 
in receptor trafficking, insertion, and single-channel conductance [Williams et al. 
1998; Kelley et al. 2003; Xu et al. 2006]. 
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Figure 1.3:  Ribbon diagrams of the Torpedo nAChR (PDB:2BG9)  
1.1A) Only two of five subunits are displayed. Two major structural elements of the LBD are shown 
for two of the five subunits: the transmitter-binding site and the transition zone. The transmitter-
binding site is composed of a cluster of aromatic residues from both the principal and complimentary 
subunits and is capped by the C-loop. The transition domain consists of several loops including: Cys-
loop, β1–β2 linker, β8–β9 linker, β10–M1 linker and the M2–M3 linker. These loops are involved in 
converting structural changes at the transmitter-binding site down to the pore domain and inducing 
channel gating.  1.1B and 1.1C) Ribbon diagram of a single subunit, rotated 90° relative to each 
other. The secondary structural elements are labeled and numbered accordingly; the outer beta sheet 
is colored red (β7, β9, β10),  the inner beta sheet (β1, β2, β6) and other beta sheets are colored in 
blue, and the transmembrane helices are colored in yellow. Part of the M3–M4 loop (connecting MA 
to M3) is missing. 1.1A and text are adapted from [Gay and Yakel 2007]. 1.1B and 1.1C are adapted 
from [Unwin 2005]. 
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Ion permeation and selectivity of Cys-loop receptors  
 The primary function of the receptor channel is to reduce the energy barrier to 
ion translocation through the hydrophobic core of the cellular membrane, to 
discriminate between ions, and open and close when exposed to endogenous 
agonists. Early mutagenesis studies of the Torpedo nAChR revealed the importance 
of three rings of negative charge along the pore-lining M2 helix at positions -5’, -2’, 
and 20’ (D238, E241, and E262 for the mouse α1 subunit respectively) (Figure 1.4) 
[Karlin 2002] 2. Mutating the glutamates/aspartates at these positions to positively 
charged amino acids reduced single channel conduction of movovalent cations, and 
the effect was additive when mutations were introduced into multiple subunits [Imoto 
et al. 1988]. Reducing the negative charge at the -2’ position has a more dramatic 
effect on channel conductance than the other two positions, and can eliminate Ca2+ 
permeation of α7 receptor [Bertrand et al. 1993]. The 19’ position in anion-selective 
receptors (20’ in cation-selective receptors) has a more prominent role in 
rectification, and regulates ion concentration in the extracellular vestibule 
[Moorhouse et al. 2002].  An additional ring of charge was identified in the LBD in 
Loop A (α1-D97) using a similar experimental design, and α1-N47 and α1-E86 have 
also been proposed as putative sites that determine both ion conduction and 
selectivity [Hansen et al. 2008; Sine et al. 2009]. The local charge provided by these 
negative residues over the axial length of the receptor channel would serve as a 
funnel to attract cations into the vestibular space in the closed state and counteract 
the low dielectric environment of the lipid bilayer during ion transport in the open 
                                                 
2
 See [Miller 1989] for a review of the prime numbering system. For nAChRs, -5’ represents the far 
intracellular end of the pore-lining M2 helix, while 20’ is at the extracellular end of the pore. 
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state. It is important to note that a conformational effect of the mutagenesis in the 
charged rings cannot be completely ruled out [Kienker et al. 1994]. 
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Fig. 1.4: Schematic representation of the pore-lining (M2) helicies.   Open state conformations of 
two M2 segments of the α1 subunits of the anion-selective GlyR (A), GABAAR (B) and the cation-
selective nAChR (C) and the 5-HT3AR subunits (D). Note the tapering of the pores to a constriction at 
their intracellular end, the charged residues flanking the intra- and extracellular mouths of the 
channels and the abundance of polar residues within the channels, especially in the GlyR and 
GABAAR. Residues believed to be projecting their side chains towards the channel pore are shown, 
labeled with the amino acid three letter code and with the generalized LGIC nomenclature for M2 
domains [Lester 1992]. In addition, the lysine residue (K0′) in the cation-selective nAChR, the arginine 
(R0′) and leucine (L15′) residues in the 5-HT3AR and the serine residue (S15′) in the anion-selective 
GABAAR and GlyR are depicted as facing away from the channel axis. Note the predominantly 
hydrophobic (non-polar) extracellular part of the cation-selective LGICs contrasting with the anion-
selective LGICs, and the predominantly hydrophilic (polar) intracellular part of all of these channels. 
Figure and text modified from [Keramidas et al. 2004]. 
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 The dimensions of the ion-conducting pore of the Cys-loop receptor family 
appear to vary between receptor subtypes. In the closed-state structure of Erwinia 
Cys-loop receptor, the pore narrows to less than 3 Å at the 2’ position, which is too 
small for passage of a hydrated ion [Hilf and Dutzler 2008]. The open-state 
structures of the Gleobacter Cys-loop receptor suggest a pore diameter of about 5Å, 
which would suggest that increasing the pore diameter is an important receptor 
gating mechanism [Bocquet et al. 2009; Hilf and Dutzler 2009]. However, cryo-EM 
studies of the nAChR identifiy a pore diameter of 20Å [Unwin 2005]. Ion permeability 
studies suggest that the pore diameter of anion-selective receptors (GABAAR, GlyR) 
ranges from 5-6 Å, whereas cation-selective receptors (nAChR, 5-HT3R) range from 
7.4-8.4 Å [Keramidas et al. 2004]. Because an ion would need to partially dehydrate 
at diameters below approximately 8Å to pass through the channel [Hille 2001], the 
similarities in pore diameter from the structural and functional studies argue for 
related (if not identical) gating mechanisms for the Cys-loop receptors.  
 Several important differences exist in ion permeation between cation-
selective (nAChR, 5-HT3R) and anion-selective (GABAAR, GlyR) Cys-loop receptor 
channels. Substituted cysteine accessibility studies (SCAM) on the M2 helix have 
revealed a pattern of similar, but non-identical accessibilities to permeating ions in 
cation-selective vs. anion-selective receptors (Figure 1.4). In general, the solvent 
accessible residues in the anionic receptors are hydrophilic over the entire length of 
the M2 helix, while solvent accessible residues in the cationic receptors are more 
hydrophobic towards the top of the M2 helix and hydrophilic towards the bottom. 
Energetically, the presence of extra polar residues in the anionic receptors could 
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contribute to additional ion binding sites within these receptors that would not be 
present in the cationic receptors. This important difference is supported by the 
anomalous mole fraction effect in GlyR and GABAA receptors, which is not observed 
in nAChRs [Bormann et al. 1987; Lester and Dougherty 1998]3.  
 While there are a few examples of anion-selective nAChRs in invertebrates, 
the vast majority of nAChRs are cation-selective as are the 5-HT3 receptors. In the 
α7 nAChR, three mutations in the M2 helix were found to convert the ion selectivity 
from cations to anions: V13’T (see Figure 1.4), E-1’A, and the insertion of a proline 
between the -1’ and -2’ positions (-2’P) [Galzi et al. 1992]. The rationale for these 
mutations came from a sequence alignment of the M2 helix of the cation-selective 
α7 nAChR with the anion-selective α1 GlyR. Follow up studies from the same lab 
showed that the proline insertion was required to convert from cationic to anionic 
selectivity in the V13’T/E-1’A background α7 nAChR, but the proline insertion by 
itself or in combination with the V13’T mutation led to non-functional channels 
[Corringer et al. 1999]. The authors concluded that the proline insertion caused a 
structural rearrangement at the bottom of the M2 helix, which was compensated by a 
reduction of hydrophobicity at V13’ and charge neutralization at E-1’. The role of 
these three positions are conserved among the Cys-loop receptor family, as the 
equivalent mutations also result in an anion-selective 5-HT3R, and the inverse 
mutations (T13’V, A-1E’, P-2’∆) resulted in a cation-selective α1 GlyR [Keramidas et 
al. 2000; Gunthorpe and Lummis 2001]. Interestingly, the E-1’A mutation by itself 
eliminates Ca2+ permeability in α7 nAChRs, and the inverse A-1’E mutation confers 
Ca2+ permeability in the α1 GlyR [Keramidas et al. 2004].  These studies 
                                                 
3
 See [Lester 1991] for a review of the AMF effect and applications to ion channel research. 
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demonstrate that the 13’ position, -1’ position, and the conformation at the 
intracellular end of the pore (proline insertion/deletion) are necessary and sufficient 
to determine ion selectivity in the Cys-loop receptor family.  While these data are 
from homomeric receptors, they illustrate that determinants of ion selectivity are 
largely conserved within the Cys-loop receptor family. 
  
Gating of Nicotinic Receptors 
 For the nicotinic receptor subfamily, acetylcholine and other agonists interact 
with aromatic residues in the binding pocket through pi-cation interactions [Meyer et 
al. 2003; Xiu et al. 2009]. The critical aromatic residues are part of the C-loop, the 
principal side, and the complementary side of the agonist-binding site. Agonist-
binding leads to a closure of the C-loop over the binding pocket [Hansen et al. 2005], 
which dramatically increases the probability of a transition into the open, ion-
conducting state. The position of the C-loop is highly variable due to thermal motion, 
which is probably responsible for the low probability of receptors to open in the 
absence of agonist [Venkatachalan and Czajkowski 2008; Wang et al. 2009b].  After 
agonist binding, a series of structural transitions are allosterically transmitted to the 
activation gate at the -3’ to 2’ positions in the M2 helix [Imoto et al. 1988; Lester 
1992; Wilson and Karlin 2001].  
 The first kinetic description of the closed-open isomerization of muscle 
nAChRs was described by Neher and Sakmann, who won the Nobel Prize in 1991 
for their development of the patch clamp technique [Neher and Sakmann 1976; 
Neher et al. 1978; Sakmann et al. 1980; Colquhoun and Sakmann 1981]. This 
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permitted a detailed analysis of the kinetics of activation, de-activation, and 
desensitization at the single-channel level. The kinetics of the muscle nAChR are 
best described by a multi-state mechanism (Figure 1.5), where the receptor can 
transition into multiple open states from the unliganded, mono-, or di-liganded 
conformations [Colquhoun 1998]. Under physiological conditions, gating of the 
muscle-type nicotinic receptors is an “all-or-none” event.  A high concentration of 
acetylcholine is needed to enter the diliganded-closed state, which than quickly 
isomerizes to the diliganded-open state. Ion permeation then rapidly terminates by 
when the receptor enters diliganded-desensitized state. Rapid onset and termination 
of ion permeation is critically important for synaptic function of the nAChRs, as 
mutations that enhance or inhibit channel gating have been linked to congenital 
myasthenia syndromes and epilepsy [Steinlein 2007]. The significance of single 
channel events are observable in recordings from in vitro brain slices, where 
activation of single or small populations of the α7 nAChRs can enhance neuronal 
excitability and trigger voltage-gated ion channels in the CNS [Gusev and Uteshev 
2009]. Therefore, understanding the mechanisms by which nAChRs transition 
between kinetic states is important for understanding physiological function. 
 From the agonist-bound ion conducting state(s), the nicotinic receptors can 
isomerize back to one of multiple closed states or desensitized states [Elenes and 
Auerbach 2002], which show higher affinity for agonists but no ion conduction [Boyd 
and Cohen 1980; Sine and Taylor 1982]. The rate of desensitization depends on the 
status of the activation gate, as faster rates are observed in the diliganded-open 
state than other open or closed states [Auerbach and Akk 1998].  However, the rate 
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of desensitization is directly proportional to the number of agonist-binding sites, as 
inactivation of individual binding sites on an α7 nAChR/5HT3 chimeric ion channel 
slows the rate of desensitization [Rayes et al. 2009]. In this respect, desensitization 
represents a complex allosteric interaction between the agonist-binding sites and 
activation gate.    
 One such approach to study the energetic relationships between the closed 
and open states is rate-equilibrium free energy relationships (REFER). The 
equilibrium rate constant (Keq) for ion channels is defined as the rate of channel 
opening (ko) divided by the rate of channel closing (kc): Keq = ko/kc. In REFER 
analysis, ko and Keq are determined using single channel recordings for receptors 
carrying at 3-4 mutations at a single residue using single channel recordings, and 
are plotted as log ko vs. log Keq (Figure 1.5). If there is a linear relationship between 
log ko and log Keq, the slope of the fit is defined as Φ. Phi values always exist 
between 0 and 1, and sample the energy landscape between the closed and open 
states.  While there are several biophysical interpretations of Φ, Auerbach and 
colleagues have used a temporal interpretation of the resulting Φ-values to suggest 
blocks of coordinated motion within the muscle-type nAChR [Auerbach 2007]. In the 
temporal interpretation of Φ-values, phi values close to 1 suggest the residue 
mutated affects early transitions (closer to the closed state) and phi values closer to 
0 suggest that the residue mutated affects later transitions. Their extensive work 
suggests coordinated motion (Φ-blocks) starting with the agonist-binding site (C-
loop, β4-β5 loop, and β7-β8 loop) and then moving through the transition zone (Cys-
loop and β1-β2 loop) and the pore region (M2 helix) to the gate of the channel 
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[Grosman et al. 2000; Chakrapani et al. 2004; Chakrapani and Auerbach 2005; Jha 
et al. 2007; Purohit and Auerbach 2007a; Purohit and Auerbach 2007b]. This 
proposed “conformational wave” propagates throughout the receptor in 
approximately 1 µs [Grosman et al. 2000]. Although REFER analysis provides a 
comprehensive view of the kinetics of the transition from the closed to open state, it 
does not provide any information about the specific structural rearrangements that 
occur.  
 
Figure 1.5: Single channel kinetic scheme for the muscle nAChR.  
(A) shows a generalized cyclic three-state kinetic scheme for any desensitizing ion channel. [C] is the 
closed state where the agonist [A] has not yet bound to the receptor [R], and is non-conducting. [O] 
is the open state, where agonist has bound to the receptor and the receptor is in the ion-conducting 
state [AR*]. [D] is the desensitized state, which has higher affinity for agonists and the agonist 
remains bound [AD] but is non-conducting. The agonist must dissociate from the desensitized 
receptor to return to the closed state [AD → A + R]. Each isomerization (C↔O, O↔D, or D↔C) can 
occur bi-directionally, and depends on the equilibrium constant (forward reaction divided by reverse 
reaction). The kinetic isomerization that leads to the highest open probability of the receptor is defined 
as the equilibrium gating constant [Keq], which is calculated from the opening rate [β] divided by the 
closing rate [α] and is shown in (B). (C) shows the mathematical relationship between β and Keq, 
where the linear slope equals Φ in the rate-equilibrium free energy relationship (REFER) [Auerbach 
2007]. (D) shows multi-state kinetic scheme for the muscle (α1(2)β1γδ/ε) nAChR. The pathway 
outlined in red represents a well-validated simplification of this reaction scheme, This is probably an 
oversimplification of the continuous wave of conformational changes that occurs during activation. 
[Colquhoun and Hawkes 1981; Sine and Steinbach 1986; Sine and Steinbach 1987; Auerbach and 
Akk 1998; Purohit et al. 2007; Purohit and Auerbach 2007a; Purohit and Auerbach 2007b]. Under 
physiological conditions, the high synaptic concentration of ACh shifts the equilibrium in the forward 
direction; sequential binding of two agonist molecules to each receptor (C→C1→C2) dramatically 
increases the open probability of the receptor (β>>>k
-2), which leads to a gating transition (C2→O2). 
From the primary open state, the receptor then transitions to the desensitized state (C2→D2, k3>>>α). 
Degradation of ACh in the synaptic cleft by acetylcholine esterase dramatically lowers the ACh 
concentration, and leads to the ultimate transition of the desensitized state back to the unliganded 
closed state (D2→C). 
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Structural transitions during nAChR gating 
  The structures of the different AChBPs and the AChBP/Torpedo chimeric 
model of a full-length nicotinic acetylcholine receptor serve as a template to 
generate homology models for other nAChRs and Cys-loop family receptors. These 
structural models provide a starting point to test hypothetical mechanisms of 
conformational changes resulting from agonist binding that lead to channel opening. 
From these models, Unwin originally proposed that a rigid-body rotation of the alpha-
subunits was the predominant molecular movement that coupled agonist binding to 
channel gating [Horenstein et al. 2001; Unwin 2005]. Subsequent work utilizing 
SCAM [Lyford et al. 2003; McLaughlin et al. 2007] and proton binding-unbinding 
reactions of ionizable residues [Cymes et al. 2005] argue against a rigid-body 
subunit rotation as the sole mechanism of agonist-induced conformational change. 
Overall, subtle rearrangements around the agonist binding site are thought to 
propagate through the rigid β-sheets to induce conformational changes in the 
transition zone, which then propagate towards the M2 helix and the channel gate 
[Wilson and Karlin 2001; Mukhtasimova et al. 2005; Sine and Engel 2006; Gay and 
Yakel 2007].  
 The “conformational wave” model of receptor gating proposes that structural 
rearrangments occur in discrete groups. One of the first structural movements of the 
Cys-loop receptor family is that of the C-loop (Figure 1.3). The C-loop occupies 
distinct conformations when bound to agonists vs. competitive antagonists, 
demonstrating that movement of the C-loop is one of the first conformational 
changes associated with receptor gating [Hansen et al. 2005]. Disulfide trapping 
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experiments have shown that the C-loop is a highly flexible structure and may move 
upwards of 5Å from the closed to open state of the GABAAR [Venkatachalan and 
Czajkowski 2008]. Induced closure of the C-loop over the agonist-binding site (using 
targeted molecular dynamics) correlates with ion flooding of the receptor pore, 
further suggesting C-loop closure is necessary and sufficient to induce the 
“conformational wave” that leads to an open (ion-conducting) receptor [Wang et al. 
2009b].  
 After closure of the C-loop, normal mode analysis of a α7 nAChR homology 
model suggests that a quaternary twist is the predominant structural rearrangement 
[Taly et al. 2005; Taly et al. 2006]. In this motion, the ligand-binding domain rotates 
counterclockwise while the transmembrane domain rotates clockwise (as viewed 
looking down the ion-conduction path from the extracellular side) [Taly et al. 2005; 
Taly et al. 2006]4. Other simulations of the α7 and muscle-type nAChRs that include 
the intracellular domain suggest that the predominant structural transitions also 
contain asymmetric motions, where one subunit moves before the other four 
subunits of the assembled receptor independent of the type of motion [Szarecka et 
al. 2007; Yi et al. 2008]. Within a subunit, the capping of the C-loop propagates a 
conformational change along the outer beta sheet (β7, β9, β10) towards the Cys-
loop and M2-M3 linker, while the transmembrane domains undergoes a combination 
of twisting and tilting motions [Cheng et al. 2007; Szarecka et al. 2007]. Tilting of the 
M2 helices was also observed in a comparison of x-ray crystallography structures in 
the closed and open state of bacterial Cys-loop receptors [Hilf and Dutzler 2008; Hilf 
                                                 
4
 Supplemental videos demonstrate this motion [Taly et al. 2005].  
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and Dutzler 2009].  Conformational changes of the M2 helices are thought to relax 
the open channel gate between the -3’ and 2’ positions.  
 In cation-selective Cys-loop receptors, another structural feature important for 
gating is the presence of a hydrophobic girdle between the 9’ and 17’ positions 
(Figure 1.4),which is large enough to fill with water molecules but excludes 
permeable cations in closed-state receptor models [Keramidas et al. 2004; 
Beckstein and Sansom 2006].   This model only applies to nAChRs (and likely 5-
HT3Rs), as the anion-selective Cys-loop receptors lack the solvent exposed 
hydrophobic residues that contribute to the girdle. Simulations of Cl- translocation in 
α1 GlyR suggest a more variable energy barrier in the M2 helix [Ivanov et al. 2007] 
For cation-selective Cys-loop receptors, the “conformational wave” would converge 
on both the hydrophobic girdle and the channel gate (further down the M2 helices) to 
allow ion-permeation as a result from the binding of agonists. 
  While there is compelling evidence for C-loop movement during receptor 
gating, the specific conformational changes that occur downstream of the agonist-
binding site remain a mystery.  The substituted cysteine accessibility method 
(SCAM) provides a powerful approach to study conformational change in ion 
channels, and complements models of receptor gating dervied from structural and 
computational studies [Akabas et al. 1992; McLaughlin et al. 2007]. This 
methodology takes advantage of the fact that cysteines introduced at specific 
positions in the protein have a very specific chemical reactivity to 
methanethiosulfonate (MTS) reagents. Hydrophillic MTS chemicals preferentially 
modify the introduced cysteine at the surface of the protein, exposed to the aqueous 
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environment. The advantage of SCAM is that it can also be used to measure the 
reactivity of MTS reagents in the presence or absence of various agonists, 
antagonists, or modulators. Differences in the rate of MTS modification are 
interpreted as being caused by conformational changes of the protein that move the 
introduced thiol or by change in the local electrostatic environment that surrounds 
the introduced thiol. By using SCAM to probe the rates of accessibility in the closed, 
open and desensitized states, the gating domain has been localized to the bottom 
third of the M2 helix of muscle nAChRs [Wilson and Karlin 2001]. Work from our 
laboratory using SCAM has shown that the LBD of the α7 nAChR undergoes 
agonist-dependent conformational changes in the inner β-sheet (β1, β2, and β6), the 
outer β-sheet (β7, β9, and β10) and the β8-β9 loop [Lyford et al. 2003; McLaughlin 
et al. 2006; McLaughlin et al. 2007].  
Because of its critical location between the LBD and TMD, mutagenesis 
studies in transition zone (TZ) have been an active area of research to understand 
nAChR gating. Fusion of the AChBP to the transmembrane domain of the 5-HT3A 
receptor (AChBP/5-HT3) produced a protein that was properly trafficked to the cell 
surface but was non-functional [Bouzat et al. 2004]. However, receptor function was 
restored to the AChBP/5HT3A chimera when all residues from the AChBP in the 
transition zone (β1-β2, Cys loop, β8-β9) were replaced with those of the 5-HT3A 
receptor. These results demonstrated that functional coupling between agonist 
binding and channel gating requires specific structural compatibility in the TZ 
[Bouzat et al. 2004]. While specific residue interactions for channel gating are known 
for different Cys-loop receptors, they are not necessarily conserved. For example, 
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Lee and Sine [Lee and Sine 2005] argue that a salt bridge between residues in the 
β1-β2 loop and the pre-M1 region in muscle nAChR (E45-R209) is critical for gating 
of muscle-type nAChRs, as shown by charge reversing mutations (E45R/R209E) 
and REFER analysis.  However, subsequent work has argued against a salt-bridge 
at the E45-R209 position in muscle-type nAChRs. First, charge-reversing mutations 
argue for a salt bridge in GABAc receptors, but they are not formed in 5-HT3 
receptors [Price et al. 2007]. Second, extensive mutagenesis using natural and 
unnatural amino acids argues that the balance of positive and negative charges in 
the TZ controls gating rather than pairwise residue interactions [Xiu et al. 2005]. 
Third, the E45L/R209A double mutation has a nearly identical Keq value and multiple 
double mutations at these positions are functional, arguing against a salt bridge 
mechanism [Purohit and Auerbach 2007a]. Another example of a specific residue 
interaction is a cis-trans isomerization of a highly conserved proline in the M2-M3 
loop of 5-HT3A receptors (P307) and α7 nAChRs (P261) [Lummis et al. 2005]. 
However, there is no proline at the equivalent position in either GABAA (lysine for β1 
GABAAR, threonine for α1 GABAAR) or glycine receptors (lysine for α1 GlyR) [Bera 
et al. 2002]. Proline has a cyclic (cis), hydrophobic R group which leads to a non-
variable Ψ angle5 and conformational rigidity. In contrast, lysine is positively charged 
at physiological pH and threonine has a polar –OH side chain and both of these 
amino acids are conformationally flexible. The differences in the sequence alignment 
and amino acid chemistry for the cis-trans isomerization of proline demonstrate that 
there is no single, conserved transduction mechanism from agonist binding to 
                                                 
5
 The Ψ dihedral angle describes the rotation around the Cα-C(O) bond. 
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channel gating. Rather, each Cys-loop receptor may employ a unique transduction 
mechanism that depends upon the charge profile of the transition zone.  
   
Positive allosteric modulation 
  In 1965, Monod, Wymann and Changeux (MWC) introduced a model of 
allosteric transition in which a protein can exist in multiple conformational states and 
that the binding of small molecules can stabilize it in a preferred conformational state 
[Monod et al. 1965]. While this model was originally developed for enzymes, the 
same principles can be applied to ligand-gated ion channels and other membrane 
proteins [Changeux and Edelstein 2005]. The main principles of the MWC model as 
applied to nAChRs are that: 1) the receptor can thermodynamically transition 
between conformational states (Figure 1.5), 2) binding of an agonist at the agonist-
binding (orthosteric) site causes a conformational change in a distal region of the 
protein. One important difference in applying the original MWC model to ligand-
gated ion channels is that competitive and non-competitive antagonists do not have 
a higher affinity for the resting/closed state, arguing against the postulate that ligand-
binding stabilizes the channel in a preferred conformational state (also called the 
“concerted” state model) [Krauss et al. 2000]. Each class of ligand (agonist, 
antagonist, modulator, etc.) does not alter a preexisting equilibrium between the 
closed and open states for the Cys-loop receptor family, and supports the conclusion 
that there is no unifying mechanism for ligand-induced conformational changes. By 
definition, nAChR agonists and competitive antagonists bind at the orthosteric site, 
but a sequential mechanism best fits radioligand binding and single channel REFER 
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data from the muscle type nAChR [Koshland et al. 1966; Auerbach and Sachs 1983; 
Krauss et al. 2000]. In this model, binding of agonists induces specific 
conformational changes that lead to receptor gating. Competitive and non-
competitive antagonists may simply occlude specific conformational changes along 
the gating transition, or induce different conformational changes to block the gating 
transition.   
In contrast, positive allosteric modulators (PAMs) bind away from the 
orthosteric site and lower the energy required to transition between conformational 
states [Bertrand and Gopalakrishnan 2007]. For ligand-gated ion channels, PAMs 
enhance agonist-evoked currents by increasing the peak current amplitude and/or 
lowering the EC50 for agonist. Mechanistically, PAMs could enhance agonist-evoked 
currents by: 1) increasing the binding affinity for agonists, 2) increasing the opening 
rate (β) of the receptor, 3) reducing receptor desensitization (which could reflect 
changes in agonist binding and/or gating), or 4) a combination of all of the above. 
Ultimately, the binding of PAMs to their target receptor would add additional energy 
to the agonist - receptor complex (Figure 1.2), allowing more of the energy 
associated with agonist-binding to drive the C-O gating isomerization [Jackson 
1989].  
The specific mechanisms of positive allosteric modulation are slowly 
emerging for the Cys-loop family of ligand-gated ion channels. At the single channel 
level, PAMs can increase the mean open time but their mechanism of action in the 
absence of agonist is not well-defined [Hurst et al. 2005]. By definition, PAMs can 
only enhance channel function in the presence of an agonist. The best known 
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example of positive allosteric modulation is benzodiazepine acting on GABAA 
receptors [Greenblatt et al. 1981; McKernan et al. 2000]. These compounds bind at 
the interface of the α1 and γ2 subunits at a non-functional agonist-binding site (at the 
interface between two subunits that is homologous to the orthosteric site), making it 
an allosteric binding site [Kucken et al. 2000; Atack 2003]. With the success of 
benzodiazepines, there is a growing interest in developing PAMs for the nAChRs. 
Positive allosteric modulators targeting the α7 nAChR have shown better specificity 
for this isoform compared to natural and synthetic agonists. [Daly 2005; Bertrand 
and Gopalakrishnan 2007].. Because allosteric modulators require the presence of 
the neurotransmitter agonist, the timing of endogenous synaptic transmission is not 
disrupted and PAMs can also enhance the activity of endogenous partial agonists, 
such as choline activation of the α7 nAChR [Gusev and Uteshev 2009]. This last 
point is crucial; by enhancing the amplitude of neurotransmission without disrupting 
the frequency and synchrony of signaling between different regions of the brain, 
PAMs should have reduced occurance and severity of side effects compared to 
orthosteric ligands. Academic and pharmaceutical industry researchers are actively 
developing allosteric modulators for ligand-gated ion channels (α7 and α4β2* 
nAChRs) and GPCRs (mAChR and mGluR subtypes) [Conn et al. 2009; Taly et al. 
2009]. 
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Positive allosteric modulation of α7 nAChRs 
  Over the last several years there has been great success in developing 
synthetic PAMs for the α7 nAChRs from diverse chemical templates (Figure 1.2) 
[Bertrand and Gopalakrishnan 2007].  The discovery that two PAMs, PNU-120596 
and TQS, not only enhance peak current amplitudes but also eliminate macroscopic 
desensitization during continuous application of these compounds with agonists led 
to a classification system based on the presence or absence of the desensitization 
“phenotype.”. PAMs that reduce or eliminate desensitization of the α7 nAChR are 
classified as Type II modulators, while PAMs that do not alter receptor 
desensitization are classified as Type I modulators [Gronlien et al. 2007].  
 The chemotype of the different positive allosteric modulators does not 
correlate with effects on receptor desensitization; for example, PNU-120596 and NS-
1738 are very similar in structure (amide linker flanked by 5/6 carbon rings) but act 
as Type II and Type I modulators, respectively [Gronlien et al. 2007]. However, the 
important difference between Type I vs. Type II modulators may be the location of 
the binding sites for these compounds. The putative PNU-120596 binding site lies in 
the intrahelical space of the four transmembrane helices, but the binding sites for 
NS-1738 and galanthamine (Type I modulators) are in the extracellular ligand-
binding domain [Hansen and Taylor 2007; Bertrand et al. 2008; Young et al. 2008]. 
In our model, PNU-120596 would stabilize the open state and lower the energy 
barrier to transition to the open state from either the closed state or the desensitized 
state in part because of its close proximity to the receptor gate. 
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 In additional to small organic molecules, physiological concentrations of Ca2+ 
allosterically modulate the α7 nAChR [Mulle et al. 1992; Vernino et al. 1992]. Under 
the current Type I/Type II nomenclature, Ca2+ and other permeable divalent cations 
behave as Type I PAMS, which do not have any effect on macroscopic 
desensitization [Sands et al. 1993; Eddins et al. 2002a; McLaughlin et al. 2006]. 
Changes in extracellular Ca2+ are well documented in the brain and can range 
anywhere from 1-3 mM under physiological conditions, with total available calcium 
(bound and free) decreasing with age [Jones and Keep 1988; Cohen and Fields 
2004]. The exact EC50 for Ca2+ modulation of wildtype α7 nAChRs is unknown, but 
reductions in extracellular Ca2+ are likely to reduce ACh-evoked currents through the 
α7 nAChR. This could have implications for the Ca2+-dependent processes such as 
vesicle fusion and synaptic plasticity Furthermore, the mechanisms of modulation by 
Ca2+ are unknown, as increases in extracellular Ca2+ decreases single channel 
amplitude but increase receptor gating [Mulle et al. 1992; Vernino et al. 1992]. 
  The conformational changes induced by PAMs for the Cys-loop receptor 
family are just emerging. Based on the work of Pless et al. [Pless et al. 2007], it is 
likely that PAMs cause a combination of similar and different conformational 
changes than agonists. Since PAMs do not directly activate their target receptor, 
conformational changes that are similar to agonists would likely induce a subsection 
(but not all) of the gating conformational wave. Benzodiazepines induce a 
conformational change at their binding site of GABAA receptors [Teissere and 
Czajkowski 2001; Kloda and Czajkowski 2007], but the conformational changes 
induced by binding of PAMs to nAChRs are unknown.  
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 To date, several α7 nAChR PAMs have shown promise in pre-clinical models 
of neuropsychiatric diseases including Alzheimers Disease and schizophrenia [Hurst 
et al. 2005; Timmermann et al. 2007]. Impairment of sensorimotor gating is a 
common symptom in human patients suffering from schizophrenia, and is thought to 
contribute to the cognitive symptoms (impaired attention and memory, poor decision-
making) by imparing the patient’s ability to filter out irrelevant stimuli from the 
external environment [McGhie and Chapman 1961; Braff et al. 1992]. Assays for 
sensorimotor gating include prepulse inhibition (auditory or visual stimuli,) EEG of 
human patients measuring the P50 wave, and hippocampal EPSP recordings to 
evoked auditory potentials in anestheized or free-behaving animals. These different 
techniques are related, in that subject/animal is exposed to a conditioning stimulus, 
followed by a test stimulus. In healthy subjects/animals, the amplitude of the test 
stimulus should be smaller than the amplitude of the conditioning stimulus; the test 
stimulus is effectively filtered by the reduction in amplitude. In schizophrenic patients 
and animal models of impaired sensorimotor gating, there is no reduction in 
amplitude between stimuli; the test stimulus is not filtered. The involvement of the 
nAChRs in schizophrenia is well-established, as patients self-medicate with nicotine 
products and the expression of the α7 nAChR is reduced in the hippocampus and 
prefrontal cortex. [Hughes et al. 1986; Freedman et al. 1995; Guan et al. 1999]. The 
Type II modulator PNU-120596  can partially restore auditory gating deficits in D-
amphetamine treated rodents, demonstrating that  this class of drug could be 
effective as an anti-schizophrenic agent in humans.  
 35 
While these previous studies have demonstrated that PNU-120596 and 
permeable divalent cations are PAMs of the α7 nAChR and synthetic PAMs have 
therapeutic potential, more work is needed to understand how these compounds 
enhance receptor gating. The mechanisms that determine type I vs. type II 
modulation are unknown; it is also unclear how changes in macroscopic 
desensitization affect physiological systems. Prolonged activation of α7 nAChRs is 
predicted to cause Ca2+-induced cellular toxicity, as a gain-of-function mutation 
(L9’T) that increases receptor open probability, neuronal apoptosis, and is lethal by 
post-natal day one in mouse models when two copies are present [Orr-Urtreger et 
al. 2000]. However, a recent study showed that PNU-120596 has no cytotoxic 
effects in heterologous and primary neuronal cell cultures [Hu et al. 2009]. These 
results6 suggest that allosteric modulation by PNU-120596 (and likely other type II 
PAMs) is attenuated in vivo, underlying the importance for a mechanistic 
understanding of positive allosteric modulation.  
The following work will investigate how Type I versus Type II PAMs induce 
conformational changes in the α7 nAChR, and how those structural transitions 
compare to those of the agonist acetylcholine. In addition, I developed homology 
models of α7 receptors from the structures of bacterial Cys-loop receptors and I 
experimentally tested the ability of these models to predict conformational changes 
associated with receptor gating. 
                                                 
6
 It is unknown how Type I vs Type II PAMs would effect nAChRs on non-neuronal cells; the α7 
nAChR is important in the cholinergic anti-inflammatory pathway but the role of PAMs and receptor 
desensitization in non-neuronal systems has not yet been investigated [Wang et al. 2009a]. 
  
 
CHAPTER 2 
 
 
MATERIALS AND METHODS 
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Reagents and Molecular Biology  
 Female Xenopus laevis frogs were obtained from Xenopus One (Dexter, MI, 
USA) or Xenopus Express (Brooksville, FL, USA). Methanethiosulfonate chemicals 
were obtained from Toronto Research Chemicals (Toronto, ON, Canada). PNU-
120596 was obtained from Tocris Bioscience (Ellisville, MO, USA). Quikchange® 
site-directed mutagenesis kit was obtained from Stratagene (La Jolla, CA, USA) and 
the mMessage mMachine® in vitro RNA transcription kit was obtained from Ambion 
(Austin, TX, USA). All other reagents for molecular biology, oocyte dissection, and 
electrophysiological recordings were obtained from Sigma-Aldrich (St. Louis, MO, 
USA) or Fisher Scientific (Pittsburgh, PA, USA).  
 The chick α7 nAChR was expressed in the pAMV vector under the control of 
the T7 promoter. Mutations were introduced into C115A/L247T receptors using the 
Quikchange site-directed mutagenesis kit according to the manufacturer’s 
instructions, and were verified by DNA sequencing. All receptors contained a 
cysteine-to-alanine mutation at position 115. C115 is the only unpaired cysteine in 
the LBD , and the C115A mutation simplifies the interpretation of thiol modification 
experiments without affecting responses to ACh [McLaughlin et al. 2006] or PNU-
120596. The utility of the L247T mutation is described below (in Chapter 3). Capped 
cRNA transcripts were made as previously described [Lyford et al. 2003]. 
 
Construct expression in Xenopus oocytes 
  Xenopus laevis oocytes were surgically removed as described [Lyford et al. 
2003]. The oocytes were injected with 20 ng of α7 nAChR cRNA and were incubated 
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for 2-7 days in ND96 (96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, 5 mM 
Na-HEPES, pH 7.5) plus 50 mg/ml gentamicin and 0.55 mg/ml sodium pyruvate.  
Some cysteine mutants, displaying a peak current response to maximal ACh 
of less than 100 nA, were coexpressed with human RIC-3 protein (resistant to 
inhibitors of cholinesterase) in a 1:1 (w/w) cRNA ratio [Lansdell et al. 2005]. Dose-
response curves from several mutant α7 receptors were generated with and without 
coexpression of RIC-3. The data suggest that RIC-3 substantially increased the 
peak current amplitude without major effects on the ACh EC50 values (Table 3.3).   
 
Two-electrode voltage clamp of Xenopus oocytes 
  Oocytes were superfused with ESLC (in mM: 96 NaCl, 2 KCl 1 MgCl2, 0.1 
CaCl2, 10 HEPES-NaOH, pH 7.5), a low-Ca2+ solution that minimizes currents 
through Ca2+-activated Cl- channels. For each mutant α7 nAChR, a 5-7 point dose-
response curve was generated to ACh alone or with the addition of 1 µM PNU-
120596 or 10 mM BaCl2 (in ESLC). Dose responses for ACh with and without PNU 
were obtained from the same oocytes. Unless otherwise noted, PNU-12096 was 
preapplied for 30 seconds, and than coapplied with ACh. BaCl2 was coapplied with 
ACh. This experimental design maximized the effect of these two modulators on the 
rate of modification of MTSEA with introduced cysteines and on the efficacy of ACh-
evoked currents. For some mutant receptors, a dose response curve was generated 
for the allosteric modulator in the presence of an EC30-50 dose of ACh. All dose 
response curves were fit to a three-parameter Hill equation using SigmaPlot 9.0 
(Systat Software, San Jose, CA, USA). Data were reported as the average ± S.E.M.  
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Two-electrode voltage clamp was performed as described [McLaughlin et al. 2007]. 
Solutions were applied by gravity perfusion with a 3-5 ml/min flow rate. Oocytes 
were superfused with ESLC for at least two minutes between all drug applications, 
and current amplitudes returned to baseline.  
 To eliminate complications of run-up and run-down of current over the course 
of an experiment, all oocytes were initially treated with a maximal ACh dose 3-4 
times consecutively. Oocytes were discarded if the response to the maximal ACh 
dose varied by more than ± 10%, or corrected for run-down/run-up.  
Substituted Cysteine Accessibility Method 
 Charged MTS reagents were made fresh daily in distilled H2O and stored on 
ice, whereas neutral MTS reagents were dissolved in either DMSO or 95% EtOH 
and stored in aliquots at -20°C. Just prior to use, the cysteine-modifying reagents 
were diluted to the appropriate concentration in ESLC and were applied immediately 
to the oocytes. MTSEA was our primary test compound to screen for reactivity at 
introduced thiols, but MTSEA-biotin, MTSBn, and DTNB were also used at select 
residues.  
 We compared the ACh dose response curves of each mutant before and after 
application of a high concentration of MTSEA (0.5-10 mM for 0.5-4 minutes). For 
mutants that showed a functional effect of MTSEA, a limiting concentration of 
MTSEA (0.1-100 µM), yielding 20-50% of the maximal MTSEA effect, was 
determined empirically. To measure modification rates, the limiting concentration of 
MTSEA was applied repeatedly for 15-30 sec. In experiments with PNU-120596, 1 
µM of this compound was pre-applied for 30 seconds and then co-applied with the 
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limiting concentration of MTSEA. In experiments with agonists, an EC100 dose (which 
yields maximal peak current amplitudes) was coapplied with the limiting 
concentration of MTSEA. In all experimental conditions, the functional effect of 
MTSEA modification was tested with a ~EC50 concentration of ACh. Each 
application of ACh was applied until a peak current amplitude was obtained (~15 s), 
and than the perfusion was switched back to ESLC (wash buffer). At the end of each 
experiment, a maximal dose of MTSEA was applied (0.5-10 mM) to measure the 
effect when all accessible thiols were modified.  
 Normalized current amplitudes (It - I∞)/(Izero-I∞), where It is the current 
amplitude after the cumulative time of MTSEA exposure, I∞ is the current amplitude 
after the final maximal dose of MTSEA, and Izero is the initial current amplitude before 
modification, were fit to a single exponential decay [Pascual and Karlin 1998] using 
SigmaPlot 9.0. The pseudo first-order rate constant was determined and was divided 
by the MTSEA concentration to give the second-order rate constant (M-1sec-1). 
To test for the presence of a vestibular constriction, the ACh dose response 
of each introduced cysteine was measured before and after a fixed application of a 
neutral cysteine-modifying reagent (2mM of MTSBn, MTSEA-biotin, or DTNB for 60 
seconds) with or without a maximally activating concentration (EC100) of 
acetylcholine. The rationale and use of MTS reagents to probe the diameter of an 
ion channel domain is described elsewhere [del Camino and Yellen 2001].    
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Statistical Analysis 
  Hill equation parameters and second order rate constants were analyzed by 
one-way or two-way analysis of variance (ANOVA) with Tukey’s post-hoc test 
(SigmaStat 3.0, Systat Software, San Jose, CA, USA). P values of <0.05 were 
interpreted to indicate significant differences. 
 
Structural models of the α7 nicotinic receptor 
  A model of the chick α7 nicotinic receptor extracellular domain, based on the 
coordinates of the Lymnaea ACh Binding Protein [Brejc et al. 2001] was constructed 
as described previously [Lyford et al. 2003; McLaughlin et al. 2006]. For reference, 
L247 is located in the transmembrane domain, in the pore-lining M2 helix, 
approximately 1/3 of the pore's length from the intracellular end [Revah et al. 1991; 
Unwin 2005]. 
 
Homology Modeling and Refinement  
 Coordinates from ELIC [Hilf and Dutzler 2008] (PDB accession number = 
2vl0) and GLIC [Bocquet et al. 2009] (PDB accession number = 3eam) were used to 
generate homology models of the chick α7 nicotinic receptor (NCBI accession 
number: NP_989512) in the closed and open state, respectively.  The GLIC 
coordinates from Bocquet et al. 2009 were chosen because they were obtained at 
higher resolution, and had fewer outliers in a Ramachadran Plot than the Hilf and 
Dutzler 2009 coordinates. A truncated α7 receptor sequence, with non-
crystallographic sequence removed, was aligned using HHPred2 [Soding 2005; 
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Soding et al. 2005] and than manually refined for both models to chooses sites of 
insertions and deletions. The non-crystallographic sequence removed from the a7 
receptor corresponds to the N-terminus prior to the inner beta sheet, and the large 
cytoplasmic loop (M3-M4 loop) for both models. The coordinates of the ELIC and 
GLIC structures were fit using five-fold non-crystallographic symmetry, rendering 
each subunit identical in the final structural models7. Therefore, we used the same 
approach in designing our homology models; only one subunit was modeled using 
InsightII 2005 (Accelrys Inc, San Diego, CA) and was assembled as a 
homopentamer prior to model refinement. Both homology models were generated in 
the absence of ligand. 
 For the closed and open models of the α7 receptor, energy minimization was 
carried out using the Discover module of Insight II 2005 using Consistent Valence 
Forcefield (CVFF) parameters in vacuo [Ponder and Case 2003]. Energy 
minimization was performed using steepest descent gradient for 500 iterations or 
until the maximum derivative ≤ 10 kcal/(mol * Å), followed by conjugate gradient 
minimization for 500 iterations or until the maximum derivative ≤ 0.5 kcal/(mol * Å) 
[Allwright 1976]. After energy minimization, the closed and open state models 
converged to a final r.m.s. deviation of 0.26 kcal/(mol * Å). After each run, the 
models were manually inspected for distortion with their respective starting structure. 
                                                 
7
 Non-crystallographic symmetry (NCS) refers to multiple copies of a molecule with the asymmetric unit of the 
crystal, and the number of folds refers to the number of copies. So, a five-fold NCS would refer to a protein that 
assembles as a pentamer. NCS also refers to  refinement calculations where the electron density is averaged 
over the entire oligomeric assembly; each subunit of the oligomeric protein will be identical in the final 
structural model. NCS refinement calculations are usually necessary for protein structures of lower resolution (≈ 
>2Å) [Kleywegt 1996].  
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Models were validated in silico using Procheck and Profiles 3D [Luthy et al. 1992; 
Morris et al. 1992; Laskowski et al. 1993].  
 
Solvent accessibility and continuum electrostatics 
  Calculations were carried out on local computing resources utilizing Pentium 
IV processors and either the Ubuntu 9.04 or Red Hat Enterprise Linux operating 
systems. Solvent accessibility calculations were performed using nAccess, which 
utilizes the “rolling ball” model of solvent accessible surface area (ASA) (Hubbard 
and Thornton 1993, [Lee and Richards 1971; Shrake and Rupley 1973]. In brief, the 
solvent is reduced to a sphere of equal radius to the starting three-dimensional 
structure (1.4Å for water). The sphere of solvent is the rolled along the surface of the 
protein, where ASA is calculated as Å2. Relative surface accessibility (RSA) is 
reported as the percentage of accessibility in comparison to a tri-amino acid peptide 
of the following structure: ala-X-ala, where “X” is the amino acid being probed 
[Hubbard et al. 1991]. In silico mutagenesis was carried out after energy 
minimization, and the introduced cysteines were manually inspected for distortions in 
the χ1 and χ2 bond angles.  
 For continuum electrostatics calculations, PDB2PQR was used to convert 
PDB files to PQR files using the Parse forcefield and to generate an instruction file 
for APBS [Sitkoff et al. 1994; Dolinsky et al. 2004].  APBS was used to calculate the 
local electrostatic potential using a linearized form of the Poisson-Boltzmann 
equation [Baker et al. 2001]. A derivation and detailed explanation of this equation 
can be found elsewhere [Fogolari et al. 2002]. APBS parameters were as follows: 
 44 
protein dielectric of 2.0,  solvent dielectric of 78.54, solvent radius 1.4 Å, temperature 
of 298.15 K,  and grid spacing set to 0.5 Å. Ionic salt concentration was set to that of 
ESLC, which yields an ionic strength of  0.129 M 8 and a Debye length of 8.8 Å9. 
Atomic radii were defined as described [Shannon 1976]. The local electrostatic 
potential is reported as kT/e, where k = Boltzmann’s Constant (1.3806504 × 10−23 
Joules/Kelvins), T = Temperature (Kelvins), and e = elementary charge (1.60217646 
× 10-19 Coulombs) [Mohr et al. 2008].  
 
Model Visualization 
 Chemical structures (found at http://www.pubchem.gov) and ion channel 
kinetic schemes were generated using the freeware version of ACD/Chemsketch 
12.01. Images of x-ray crystallography data and homology models were generated 
with PyMOL 0.99 (DeLano Scientific, South San Francisco, CA) and edited using 
Adobe Photoshop 7.0 (Adobe Systems Inc, San Jose, CA). The results from APBS 
were visualized in PyMOL using an included plug-in.  MOLE was used to generate 
Voronoi mesh diagrams of ion-conducting pores, as an included plug-in for PyMOL 
[Petrek et al. 2007].  
                                                 
8
 Ionic Strength (I) = 0.5 * [Σ (ciz2], where ci = Molar concentration of ion, z = valence of ion.  
9
 Debye Length in an electrolyte (κ-1) ≈ 100/√(I), where I = Ionic Strength in mM. This simplification is valid 
for conditions at room temperature (T = 300 K) and a solvent dielectric constant of 80 [Russel 1989].  
  
 
CHAPTER 3 
 
 
PNU-120596 AND ACETYLCHOLINE CAUSE SIMILAR GATING 
TRANSITIONS IN THE EXTRACELLULAR LIGAND-BINDING 
DOMAIN OF THE α7 NICOTINIC RECEPTOR  
 46 
Introduction  
 Nicotinic acetylcholine receptors are the prototypical member of the Cys-loop 
family of ligand-gated ion channels that also includes GABAA, serotonin type 3 (5-
HT3), and glycine receptors. This family of receptors are assembled as heteromeric 
or homomeric pentamers around a central pore [Karlin 2002].  Each subunit contains 
an extracellular ligand-binding domain (LBD), an α-helical transmembrane domain 
(TMD), a transition zone that couples the LBD to the TMD, and an intracellular 
domain [Gay and Yakel 2007].  
Neuronal nAChRs are expressed diffusely throughout most of the central 
nervous system (CNS), with α4β2* and α7-containing receptors showing the highest 
levels of expression [Orr-Urtreger et al. 1997]. Of the neuronal nicotinic receptors, 
the homomeric α7 receptor is implicated in neurological diseases such as 
schizophrenia, Alzheimer’s Disease, and anxiety disorders [Gotti and Clementi 
2004]. Therefore, the α7 nicotinic receptor potentially represents an important 
therapeutic target.  
Over the last several years there has been success in developing synthetic 
PAMs for α7 nAChRs, including PNU-120596 [Bertrand and Gopalakrishnan 2007]. 
These compounds are predicted to bind away from the orthosteric agonist binding 
sites and enhance gating of the receptor in the presence of agonists. PNU-120596 is 
part of a growing class of PAMs that can reopen α7 receptors from the desensitized 
state and slow additional desensitization, designated as Type II modulators 
[Gronlien et al. 2007]. By eliminating transitions into the desensitized state, Type II 
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PAMs exert a much greater effect on α7 receptor activation than agonists or PAMs 
that do not alter desensitization (Type I modulators).  
In animal models, PNU-120596 can partially restore auditory gating deficits 
[Hurst et al. 2005], a common symptom of schizophrenia. Understanding the 
molecular mechanisms and structural determinants of PAM action could lead to the 
development of drugs for the treatment of a wide variety of neuropsychiatric 
disorders. For example, structural elements from cytisine and morphine guided the 
development of varenicline, a α4β2 partial agonist and α7 agonist that reduces drug-
seeking behavior and consumption of nicotine [Mihalak et al. 2006].  
To understand how different nAChR subtypes contribute to disease states, it 
is crucial to understand the molecular mechanisms by which these receptors couple 
the binding of agonists and PAMs to opening of the channel. Benzodiazepines, the 
archetypal positive allosteric modulators of GABAA receptors, induce conformational 
changes in the ligand-binding domain of GABAA receptors [Sharkey and Czajkowski 
2008]. We have found that agonists of α7 receptors also induce structural transitions 
in the LBD, as measured by the substituted cysteine accessibility method (SCAM) 
[Lyford et al. 2003; McLaughlin et al. 2006; McLaughlin et al. 2007]. Based on the 
existing data, we hypothesize that PAMs and agonists cause similar but non-
identical conformational changes.  
Here, we used SCAM to compare changes in cysteine accessibility caused by 
PNU-120596 and ACh. We found that PNU-120596 induced conformational changes 
in the inner beta sheet, transition zone, and orthosteric site that were similar to those 
induced by ACh. These results show that PAMs and agonists share a conserved 
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molecular mechanism regardless of their action on receptor gating and independent 
of their initial binding sites. We have identified mutations that either eliminate or 
enhance allosteric modulation to the point of full agonism. Finally, we present 
evidence that PNU-120596 does not bind at the agonist-binding site.   
 
 Results  
Figure 3.1 shows our homology model of the α7 nAChR derived from the 
structure of the Lymnaea AChBP [Brejc et al. 2001] and the regions of interest 
targeted in this study. W148 and W54 are located in the agonist-binding "pocket" 
(the orthosteric site). M37, N52, and M40 are located at the interface between 
subunits (the inner beta sheet), "below" the agonist binding pocket. These residues 
were previously shown to be good reporters of agonist-induced conformational 
changes [McLaughlin et al. 2007]. E44, N170, and E172 are located in the "transition 
zone" that couples the LBD to the TMD.  
All mutants in this study contained the well-characterized leucine 247 to 
threonine (L247T or L9'T) mutation. L247T-containing α7 receptors have 
conductance and ion selectivity that are similar to the wildtype receptor, but are 
more sensitive to acetylcholine and exhibit slower macroscopic desensitization 
[Revah et al. 1991]. L247T is a good model system for our studies because its large 
current amplitudes allow us to measure modification rates for cysteine substitutions 
with decreased functional expression levels.  All mutants also contained the C115A 
mutation, in which the single unpaired cysteine in the LBD is mutated to an alanine.  
This mutation, which has no effect on activation kinetics, ligand sensitivity, or ion 
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permeation, simplifies interpretation of cysteine modification experiments 
[McLaughlin et al. 2006].  
 
Figure 3.1: Homology model of the extracellular domain of α7 nAChR. A ribbon cartoon 
displaying two subunits of the pentameric receptor, viewed from the outside. The primary ACh-
binding subunit is shown in yellow and the complimentary subunit is in cyan. Residues of interest are 
shown as sticks and are labeled on one of the two subunits for clarity. M37, M40, and N52 are part of 
the inner beta sheet (β1, β2, β6).  E44, N170, and E172 are part of the transition zone (loop 2 and 
loop 9). W54 and W148 are part of the orthosteric (agonist-binding) site (β6, and behind the C loop). 
The residues of interest and the surrounding amino acid sequence is shown beneath the cartoon. The 
structure of PNU-120596 is shown below the chick α7 nAChR amino acid sequence. 
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We first examined if PNU-120596 acts as a positive allosteric modulator of 
C115A/L247T α7 receptors. PNU-120596 retained its modulatory effect in the 
C115A/L247T background, as measured by the ability to enhance ACh-evoked 
currents in a dose-dependent manner (Figure 3.2A). The concentration of PNU-
120596 that elicited a half-maximal modulation (when applied with an EC30-50 
concentration of ACh) was 257 ± 22 nM (Figure 3.2A), a value that is similar to that 
reported for wildtype α7 receptors (216 ± 64 nM; Hurst et al. 2005). This suggests 
that the C115A/L247T mutations do not significantly alter the affinity of PNU-120596 
for the α7 nicotinic receptor.  
PNU-120596 (1 µM) caused a left-shift of the ACh dose-response curve of 
C115A/L247T α7 receptors and a significant decrease in the EC50 for ACh (Figure 
3.2B, Table 3.1).  In contrast to the responses of wildtype α7 receptors [Hurst et al. 
2005], PNU-120596 did not cause a significant change in the current amplitudes of 
C115A/L247T α7 receptors evoked at maximal ACh concentrations.  We speculate 
that the L247T mutation increased the equilibrium gating constant of the 
receptors(Keq = β/α; Figure 1.2) [Colquhoun 1998], lowering the ACh EC50 
compared to wild-type receptors.  For receptors with a low gating constant (α >> β), 
such as wild-type α7 receptors, a PAM could increase the maximal response, 
decrease the EC50, or both. In contrast, for receptors with a high gating constant (β 
>> α,) such as L247T-containing α7 receptors, we expect PAMs to affect EC50 
alone, since the maximal response to agonist is already near 1 [Colquhoun 1998]. 
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Figure 3.2: PNU-120596 is a positive allosteric modulator of C115A/L247T α7 receptor 
and elicits opening from a partially desensitized state. (A) A maximal dose of PNU-120596 (1µM) 
enhances ACh-evoked currents. Peak current amplitude increases approximately 81% with the 
addition of PNU-120596 to a fixed dose of ACh (1µM). Traces are from the same oocyte.  (B) PNU-
120596, at the concentrations shown, was applied with an ~EC50 dose of ACh (2-3 µM). Positive 
allosteric modulation was observed as a significant enhancement of ACh-evoked current (189 ± 18%, 
n=5). The EC50 for PNU-120596 was 257 ± 22 nM (n=5). (D) ACh was applied with an EC100 dose of 
PNU-120596 (1 µM). Positive allosteric modulation was observed as a significant reduction in the 
EC50 for ACh. (Table 3.1). Data are fit to the Hill equation and are the mean value ± S.E.M, 
normalized to the maximal value of the Hill equation fit of each data set. (D) A representative trace 
showing that an EC100 dose of PNU-120596 (1 µM) is sufficient to reactivate partially desensitized 
C115A/L247T receptors (n=5). Coapplication of ACh and PNU-120596 is also sufficient to completely 
inhibit desensitization, and responses are reversible when both compounds are washed out. 
 
 5
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Table 3.1 -  Summary of ACh dose response data 
 
Mutant ACh EC50 (µM) Imax (µA) Hill Coefficient n 
ACh EC50 + 1 µM 
PNU-120596 (µM)  n Effect+ 
C115A/L247T 
background 2.4 ± 0.23 6.4 ± 0.64 2.8 ± 0.25 10 0.22 ± 0.09 (3) PAM 
Inner Beta Sheet                               
M37C 4.5 ± 1.30 0.4 ± 0.12 1.3 ± 0.10 10 1.6 ± 0.18 (7) No effect 
M40C 6.7 ± 0.70 2.2 ± 0.47 1.4 ± 0.11 16 0.58 ± 0.17 (4) PAM 
N52C 0.79 ± 0.20 0.31 ± 0.08 0.68 ± 0.07 13 N.D‡         
Transition Zone                
E44C 7.2 ± 0.56 4.6 ± 0.39 2.6 ± 0.31 10 2.5 ± 0.37 (3) PAM 
N170C† 12 ± 1.4 1.3 ± 0.24 1.6 ± 0.12 15 2.6 ± 0.56 (3) PAM 
E172C† 30 ± 2.0 0.74 ± 0.11 2.4 ± 0.10 16 41 ± 5.3 (3) No effect 
Agonist-Binding Site                
W54C 88 ± 9.7 2.3 ± 0.40 1.6 ± 0.04 12 15 ± 5.1 (5) PAM 
W148C† 205 ± 28 3.5 ± 0.52 1.5 ± 0.06 11 N.D‡         
 
+ = based on statistically significant differences between ACh EC50 with and without 1 µM  PNU-120596 (P<0.05) 
† = denotes co-expression with human RIC-3 (see Methods) 
‡ = value not determined because of agonism observed with PNU-120596 
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A unique feature of PNU-120596 is the ability to reactivate desensitized α7 
receptors in the presence of agonist, a feature defined as Type II modulation [Hurst 
et al. 2005; Gronlien et al. 2007]. Therefore, we determined if PNU-120596 could 
reactivate C115A/L247T α7 receptors following slow desensitization. A 
representative trace is shown in Figure 3.2C. As expected, C115A/L247T receptors 
showed partial desensitization during continuous application of an EC100 
concentration of ACh (100 µM, a maximally effective concentration), plateauing at 
48.2 ± 0.02% desensitization by 87.5 ± 7.0 seconds (n=5). Then, application of an 
EC100 concentration of PNU-120596 (1 µM) after partial desensitization reactivated 
the C115A/L247T receptors (n=5), consistent with Type II modulation. The 
continuous application of ACh and PNU-120596 completely blocked slow 
desensitization of C115A/L247T receptors, as observed in wildtype α7 receptors 
[Gronlien et al. 2007]. The ability of PNU-120596 to reactivate partially desensitized 
C115A/L247T receptors and prevent subsequent desensitization did not depend on 
the ACh concentration, and the subsequent introduction of cysteine mutants into this 
background also did not alter the Type II modulation properties of PNU-120596 (data 
not shown). Furthermore, the reduction in receptor desensitization caused by the 
L247T mutation was not dramatically altered by the introduction of our cysteine 
mutations into this background (data not shown).We conclude that the C115A/L247T 
mutations do not alter the affinity or kinetics of PNU-120596 (Figure 3.2A and 
3.2C), only the ability to enhance peak current amplitude (Figure 3.2B), which we 
attribute to enhanced gating of the C115A/L247T receptors. This interpretation is 
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supported by macroscopic and single-channel analysis, showing that effects on 
apparent desensitization by mutations at L9’ in other Cys-loop receptors can be 
explained by increases in mean open time alone [Filatov and White 1995; Bianchi 
and Macdonald 2001]. Therefore, α7 receptors containing the C115A/L247T 
mutation are a reasonable model to examine conformational transitions underlying 
allosteric modulation by PNU.  
For all of the cysteine mutations used in this study, we generated ACh 
concentration-response curves to probe for possible deleterious effects of the 
individually introduced cysteines on channel function. Most cysteine mutations 
generated ACh EC50 values that were not significantly different from the parent 
C115A/L247T receptor (Table 3.1), suggesting that the introduced mutations were 
well tolerated. Two mutations at the orthosteric site (W54C and W148C), 
significantly increased the ACh EC50 compared to the parent C115A/L247T receptor, 
as expected for residues required for the binding of agonists or in close proximity to 
the binding site [Brejc et al. 2001]. Unexpectedly, we found that two mutants (N52C 
and W148C) were activated by PNU-120596 alone. The EC50 values for PNU-
120596 activation were 340 ± 20 nM (n=3) and 450 ± 10 nM (n=3) for N52C and 
W148C mutant receptors, respectively. Our interpretation is that the N52C and 
W148C mutations enhance the ability of PNU-120596 to induce conformational 
changes such that it can directly gate these mutant receptors.  
Because a binding site for divalent cation modulators has been proposed in 
the transition zone [Galzi et al. 1996], we also introduced mutations at positions E44 
and E172 to test if the putative divalent cation binding site is required for modulation 
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by PNU-120596. We found that one mutation in the transition zone (E172C), and 
one mutation in the inner beta sheet (M37C), eliminated positive allosteric 
modulation by PNU-120596 (Table 3.1). These data provide evidence that M37 and 
E172 are required for binding of PNU-120596 and/or PNU-120596-induced changes 
in gating.  
To explore conformational changes in α7 receptors evoked by PNU-120596, 
we examined PNU-120596-dependent changes in the rate of MTSEA modification of 
cysteines introduced in the LBD. The ability of ligands to alter the rate of MTS 
modification of introduced thiols is interpreted as (1) steric interference between the 
ligand and the MTS reagent, (2) a conformational change of the introduced thiol 
induced by that ligand that changes the surface accessibility of the thiol, and/or (3) a 
conformational change induced by the ligand in the environment near the introduced 
thiol that alters its local electrostatic environment [Akabas et al. 1992; McLaughlin et 
al. 2007].  
It is important to note that SCAM measures the time-averaged conformational 
transition of the receptor, including closed, open, desensitized, and multiple 
intermediate states. Because the L9’T mutation increases the open time of α7 
receptors [Revah et al. 1991; Filatov and White 1995], we assume that the 
conformational changes measured in the presence of ACh are dominated by those 
relating to activation over those relating to desensitization. However, we cannot rule 
the effects of our introduced cysteines and L247T on the conformational pathways 
associated with desensitization. 
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Figure 3.3 shows an example of the protocol used to measure the thiol 
modification rate (E44C). Figure 3.3A shows an experiment from a single oocyte in 
which a sub-maximal concentration of MTSEA (1 µM) was applied between test 
applications of ACh (see Methods). The effect of covalent modification was a 
decrease in ACh-evoked currents. Figure 3.3B shows an experiment in which 1 µM 
PNU-120596 was preapplied and than coapplied with MTSEA (1 µM) between test 
applications of ACh. For clarity, only the ACh-evoked currents that were used to 
determine the rate of modification are shown. For each experiment, peak ACh-
evoked current amplitudes were plotted versus the cumulative time of exposure to 
MTSEA (Figure 3.3C). Pseudo first-order rate constants obtained from the fits of the 
data to a single exponential equation were divided by the concentration of MTSEA to 
yield the second order rate constants (k2) shown in Table 3.2.  
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Figure 3.3: PNU-120596 slows the rate of MTSEA modification at E44C. (A) Successive 
ACh-evoked currents before and after the addition of a submaximal concentration of MTSEA (1 µM, 
15 second exposures). After four successive applications, the endpoint of MTSEA modification was 
determined by a prolonged application of 500 µM MTSEA for 60 seconds. Washes of 1-2 minutes 
between drug applications are not shown. (B) The same protocol as (A), with a 30 second pre-
exposure to 1 µM PNU-120596 followed by co-application of 1 µM PNU-120596 with MTSEA. (C). 
Normalized peak current amplitudes from a single experiment are plotted against cumulative MTSEA 
exposure. The calculated pseudo first-order rate constants from these experiments are 0.0299 sec-1 
for control (A), and 0.0169 sec-1 in the presence of PNU-120596 (B). Second order rate constants (k2) 
are calculated from these values and are displayed in Table 3.2. 
 
Using this protocol, we determined the second order rate constants for 
modification of three residues in the inner beta sheet (M37C, M40C, N52C). Figure 
3.4A shows the mean second order rate constants measured in the presence of 
MTSEA alone (control), MTSEA plus ACh, and MTSEA plus PNU-120596. PNU-
120596 and ACh each caused a 7-9 fold reduction in the modification rate of M37C 
and a 5-7 fold reduction in the modification rate of M40C (Figure 3.4B). The 
modification rates in the presence of ACh or PNU-120596 were significantly different 
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from control but were not significantly different from each other. Thus, without 
activating these receptors, PNU-120596 caused changes in the accessibility or 
electrostatic environment of M37C and M40C that were similar to those caused by 
ACh [McLaughlin et al. 2007]. PNU-120596 decreased the rate of modification of 
M37C, even though receptors containing this mutation were not positively modulated 
by PNU-120596 (Table 3.1). This result demonstrates that PNU-120596 can elicit 
conformational changes in the inner beta sheet in the absence of a modulatory 
effect. Because M37 or M40 are not part of the agonist-binding site, it is unlikely that 
steric interference between ligand and MTSEA is responsible for the decreased 
modification rates observed at these positions. In contrast, PNU-120596 did not 
cause a difference in the rate of modification of N52C (Figure 3.4A and B). 
Although ACh increased the rate of MTSEA modification of N52C [McLaughlin et al. 
2007], PNU-120596 did not cause a significant change. Thus, PNU120596 caused 
some but not all of the changes in thiol accessibility in the inner beta-sheet caused 
by ACh. To verify that the conformational changes studied in L247T α7 receptors 
were similar to those in fast-desensitizing α7 receptors, we also studied cysteine 
accessibility of M40C constructed in the C115A background. This mutation was 
included because position C115 is the only solvent accessible cysteine in the LBD; 
mutation of this residue to alanine allows us to conclude that our rates of chemical 
modification are due ONLY to a reaction at the introduced cysteine. The rates of 
MTSEA modification of M40C/WT, with and without ACh, were similar as those 
measured in the C115A/L247T background (Figure 3.8). This suggests that the 
changes in accessibility we measure are independent of the C115A/L247T mutation. 
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Figure 3.4: PNU-120596 differentially alters the rate of MTSEA modification at inner β 
sheet residues. (A) Mean second-order modification rate constants (k2), calculated using the 
protocol outlined in Figure 3, at three residues in the inner beta sheet, M37C, M40C, and N52C. 
Mean values for MTSEA alone (control), MTSEA plus ACh, and MTSEA plus PNU-120596
 
are 
shown, plotted on a log scale. PNU-120596 slows the rate of modification at M37C and M40C 
compared to control but has no effect at N52C . * = Rate was significantly different from control 
(P<0.05). (B) A plot of the second order rate constant ratios. The average rate from each 
experimental condition is divided by the average control rate for each residue. Positive values 
represent an acceleration of the rate of modification and negative values represent a reduction in the 
rate of modification. 
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Table 3.2 - Second order rate constants for MTSEA modification of receptors carrying Cys substitutions in the 
extracellular domain of α7 nAChR. 
 
Mutant Control (M-1sec-1) MTSEA + ACh (M-1sec-1)  
MTSEA +  
PNU-120596 (M-1sec-1) 
MTSEA + ACh  
+ PNU-120596 (M-1sec-1) 
Inner Beta 
Sheet                                  
M37C 2470 ± 310 (12) 333 ± 152 * (6) 271 ± 104 * (7)      
M40C 16100 ± 2370 (15) 2090 ± 748 * (5) 3030 ± 313 * (5)      
N52C 250 ± 68 (8) 1320 ± 238 * (9) 390 ± 118 ‡ (4)      
Transition 
Zone 
       
 
    
 
 
 
    
E44C 33700 ± 6540 (8) 1460 ± 505 * (8) 4180 ± 637 * (5) 312 ± 19 * (5) 
N170C 3160 ± 392 (7) 5730 ± 682 * (7) 818 ± 114 *,‡ (10) 3660 ± 115  (4) 
E172C 12900 ± 1560 (9) 3450 ± 470 * (6) 2830 ± 410 * (7) 1710 ± 310 * (7) 
Agonist-
Binding Site                    
W54C 9500 ± 1330 (6) 4030 ± 770 * (5) 6080 ± 920   (4)      
W148C 45900 ± 7640 (9) 3010 ± 1100 * (6) 8830 ± 1320 * (6)      
 
* = Statistically different from Control (P<0.05).  
‡ = Statistically different from + ACh (P<0.05)
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Next, we determined the second order rate constants for the modification of 
three residues in the transition zone (E44C, N170C, and E172C). Figure 3.5A 
shows the mean second order rate constants measured in the presence of MTSEA 
alone (control), MTSEA plus ACh, and MTSEA plus PNU-120596. We observed 
differential effects of PNU-120596 in all three mutant receptors. PNU-120596 and 
ACh each decreased the rate of MTSEA modification of E44C by ~8-fold and ~21-
fold, respectively (Figure 3.5A and B). PNU-120596 and ACh both decreased the 
rate of modification of E172C by 2-5 fold, even though receptors containing this 
mutation were not positively modulated by PNU-120596 (Table 3.1). This result 
demonstrates that PNU can elicit conformational changes in the transition zone 
without enhancing agonist-evoked currents. The rate of MTSEA modification of 
N170C was altered differently by PNU-120596 and ACh. PNU-120596 significantly 
decreased the rate of modification while ACh increased the rate of modification. 
Overall, these data show that PNU-120596 induces conformational changes at E44 
and E172 that are similar to those induced by ACh, but PNU-120596-induced 
changes at N170 are different from those induced by ACh.  
We also measured the combined effects of ACh plus PNU-120596 on 
MTSEA modification at introduced cysteines in the transition zone (E44C, N170C, 
and E172C). At E44C and E172C, the combination of PNU-120596 and ACh caused 
a larger effect than that caused by either ACh or PNU-120596 alone (Figure 3.5, 
Table 3.2). At N170C, PNU-120596 and ACh had opposite effects on the rate of 
MTSEA modification. The simultaneous application both reagents gave a rate of 
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MTSEA modification was not significantly different from control. In this respect, 
combined effects of PNU-120596 and ACh lead to a net cancelation of each 
individual effect. 
 
 
Figure 3.5: PNU-120596 differentially alters the rate of MTSEA modification at residues 
in the transition zone. (A) Mean second-order modification rate constants (k2) of at three residues in 
the transition zone, E44C, N170C, and E172C. PNU-120596 significantly reduces the rate of 
modification at E44C and N170C. PNU-120596 significantly reduces the rate of modification at 
E172C, despite the lack of positive allosteric modulation at this residue (Table 3.1). At N170C, the 
rate of modification in the presence of PNU-120596 is significantly slower than in the presence of 
ACh. * = Rate was significantly different from control (P<0.05). (B) A plot of the second order rate 
constant ratios. Note that PNU-120596 slows the rate of modification of N170C while ACh increases 
the rate of modification. 
 
Because the vestibule of the LBD of nicotinic receptors is predicted to be 
highly electronegative [Unwin 2005], we also examined the rates of MTS 
modification using anionic MTS reagents (Figures 3.9-3.11).  We found that MTSEA 
modified E44C much faster than MTSCE and MTSES (Figure 3.10), even after 
accounting for the lower intrinsic rates of reaction by MTSCE and MTSES (Figure 
3.9). In addition, the effect of ACh on the rate of MTSEA modification was much 
greater than the effect of ACh on the rate of MTSCE modification. Modification of 
M40C by either MTSES or MTSCE was too slow to measure (Figure 3.11). These 
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results provide additional evidence for a highly negative electrostatic environment 
lining the vestibule of nAChRs, and suggest that changes in the electrostatic 
environment affect modification rates at residues in the inner beta sheet and 
transition zone. This highly electronegative environment could serve to focus cations 
along the ion-permeation path of the inner vestibule. Additional “rings of charge” 
have been proposed at D97 (conserved in all nAChRs except α3/α6) [Hansen et al. 
2008], and four negatively charged residues specific for the α7 nAChR (D41, D43, 
E44, and E172) in the transition zone could act as an α7-specific feature to enhance 
ion conductance.  
Figure 3.6 shows second order rate constants of MTSEA modification of two 
residues in the orthosteric agonist-binding site (W54C and W148C). ACh slowed the 
rate of modification of W54C, which agrees with previously published results on 
wildtype α7 receptors [Gay et al. 2008]. However, PNU-120596 did not significantly 
reduce the rate of modification at W54C (Figure 3.6A). ACh and PNU-120596, 
acting as agonists (Table 3.1), both significantly slowed the rate of modification of 
W148C (Figure 3.6A).  Since the aromatic side chains of W54 and W148 are both 
known to be part of the ligand-binding site, it is likely that steric occlusion by ACh is 
at least partially responsible for the slowing of modification of these Cys mutants. 
Slowing of modification of W148C by PNU-120596 could also be explained by steric 
hindrance, if PNU-120596 binds at unoccupied agonist binding sites, analogous to 
the binding site for benzodiazepines at the α-γ subunit interface of GABAA receptors 
[Gunther et al. 1995; Amin et al. 1997]. Acetylcholine (Mr=146) contains a positively 
charged choline group that makes pi-cation interactions with the agonist-binding site 
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[Zhong et al. 1998]. PNU-120596 (Mr=312) is a amide analog flanked by isoxazole 
and chloro,dimethoxyphenyl groups [Hurst et al. 2005]. Recent evidence, however, 
suggests that PAMs of α7 receptors bind to sites in the TMD [Bertrand et al. 2008; 
Young et al. 2008], and thus slowing of W148C modification by PNU-120596 could 
be explained by an allosteric effect at the ligand-binding pocket, perhaps including 
partial closure of loop C. 
 
 
Figure 3.6: PNU-120596 slows the rate of MTSEA modification at W148C, but not W54C 
in the orthosteric site. (A) Mean second order rate constants (k2) were calculated at two residues in 
the transition zone; W54C and W148C. * = Rate was significantly different from control (P<0.05). (B) 
A plot of the second order rate constant ratios. 
  
To distinguish between these possibilities we took advantage of an 
unexpected observation: Introduction of W148C in the C115A/L247T parent receptor 
converted PNU-120596 from a positive allosteric modulator to a full agonist (Table 
3.1 and Figure 3.7A). The phenotype of this receptor is useful because it allows us 
to compare the effects of covalent modification with MTS reagents on either ACh- or 
PNU-120596-evoked gating at the well-defined agonist-binding site. If PNU-120596 
activates the receptors via binding to the orthosteric agonist binding site, we expect 
that covalent modification of W148C in the agonist binding pocket to disrupt 
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activation by both ACh and PNU-120596 similarly via steric effects on ligand binding. 
If PNU does not activate W148C mutants by binding at the agonist binding site than 
PNU-evoked currents should be less sensitive to covalent modification of W148C 
then ACh-evoked currents. For these experiments, we used two MTS reagents of 
different size and charge to determine moiety-dependent affects on ACh and PNU-
evoked current at W148C. MTSEA adds a positively charged ethyl amine to thiols at 
physiological pH, and is comparatively small. MTSEA-biotin adds a neutral, bulky 
ring structure to thiols and is comparatively large.  
Figure 3.7B shows representative ACh- and PNU-120596-evoked currents 
before and after modification of W148C by MTSEA (100 µM for 60 seconds). This 
exposure to MTSEA was sufficient to completely eliminate ACh-evoked current, but 
it had no effect on currents evoked by PNU-120596. If we assume that modification 
of a binding site residue interferes with activation by steric interference with ligand, 
than this result implies that PNU-120596 activates receptors via a site distinct from 
the orthosteric site.  However, an alternative explanation is that the two ligands 
interact with a different set of "contact points" in the binding pocket, and those for 
PNU-120596 are removed from the ethyl amine adduct at W148.  To test this, we 
examined the effect of MTSEA-biotin, which modifies the thiol with a bulky ring 
structure.  Figure 3.7C shows representative ACh- and PNU-120596-evoked 
currents before and after modification of W148C by MTSEA-biotin (4 µM for 60 
seconds). This exposure of MTSEA-biotin was sufficient to reduce ACh-evoked 
current by 70%, but had no significant effect on the magnitude of currents evoked by 
PNU-120596. Modification of the agonist binding site by MTSEA-biotin slowed the 
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kinetics of PNU-120596-dependent activation (Figure 3.7C), suggesting that there 
are allosteric conformational changes at the agonist binding site during activation by 
PNU-120596. The results from multiple experiments are summarized in Figure 
3.7D. Covalent modification of W148C by MTSEA and MTSEA-biotin had a 
significantly greater effect on ACh-evoked current than on PNU-120596-evoked 
currents (P<0.01). This observation provides evidence that, while behaving as an 
agonist, PNU-120596 does not interact with the agonist-binding site of α7 receptors. 
Our interpretation is that PNU-120596 induces conformational changes at the 
agonist-binding site through allosteric mechanisms, rather than steric occlusion, 
because occlusion is predicted to impair both ACh and PNU-evoked currents 
similarly. 
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Figure 3.7: Covalent modification of W148C in the orthosteric site does not affect 
agonism by PNU-120596. (A) PNU-120596 acts as a full agonist of W148C/C115A/L247T α7 
receptors. Hill parameter fits for activation by ACh are in Table 3.1. For PNU-120596, the EC50 is 
0.45 ± 0.01 µM, Imax is 3.87 ± 0.65 µA, and Hill Coefficient = 6.79 ± 0.81 (n=3). PNU-evoked currents 
are normalized to peak ACh-evoked current (I/IACh).(B) Representative traces for 3 mM ACh and 3 µM 
PNU-120596 shown before (black) and after (red) application of 100 µM MTSEA for 60 seconds. (C) 
Representative traces for 3 mM ACh and 3 µM PNU-120596 shown before (black) and after (red) 
application 4 µM MTSEA-biotin for 60 seconds. (D) Summary data for the effects of covalent 
modification of W148C with MTSEA (n=8) and MTSEA-biotin (n=10) on ACh and PNU-evoked 
currents. Bars represent the percentage of ACh or PNU-evoked current after MTS modification 
relative to the control currents before modification (Iafter/Ibefore). Both MTSEA and MTSEA–biotin 
caused a significantly greater reduction in ACh-evoked currents than PNU-evoked currents (* 
P<0.01). 
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Discussion  
In this study, we provide evidence that the positive allosteric modulator PNU-
120596 causes conformational changes in the LBD of α7 nicotinic receptors that 
partially overlap with those caused by ACh.  We focused on mapping the structural 
transitions of PAMs in three regions of the LBD: 1) The inner beta sheet, 2) the 
transition zone, and 3) the orthosteric site (Figure 3.1). A homology model of the 
LBD of the α7 receptor, based on the structure of AChBP, was used to guide our 
experiments [Brejc et al. 2001; Lyford et al. 2003]. 
 
Figure 3.8: ACh reduces the rate of MTSEA modification in M40C/C115A α7 receptors. MTSEA 
modification experiments were performed as described in the Methods section. The rate of MTSEA 
modification of M40C/C115A in the absence of ACh was 31900 ± 2830 M-1s-1 (n = 5), and the rate of 
modification in the presence of ACh was 1830 ± 261 M-1s-1 (n = 4). ACh significantly reduces the rate 
of MTSEA modification by approximately 18-fold (P < 0.001), similar to M40C/C115A/L247T receptors 
(Table 2).  
 
 The inner beta sheet, comprised of the β1, β2, and β6 strands, resides at the 
interface between two subunits (Figure 3.1). In this study, we found that PNU-
120596 caused reductions in the rate of modification of M37C and M40C that were 
similar to those caused by ACh (Figure 3.4, Table 3.2, [McLaughlin et al. 2007]). 
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The similarity in the effects on cysteine modification at M37C and M40C suggests 
that PAMs and agonists induce similar conformational changes in the LBD of α7 
receptors. We have provided the first evidence that PAMs of α7 receptors enhance 
gating by causing some of the same structural transitions in the LBD as ACh.  
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Figure 3.9: Intrinsic reaction rates of charged MTS reagents. Comparison of the rates of 
modification of 5-Thio-(2-nitrobenzoic acid) (TNB) by MTSEA, MTSES, and MTSCE. 5,5'-Dithio-bis(2-
nitrobenzoic acid) (DTNB) was dissolved in Tris buffer (100 mM Tris HCl, pH 8.0) and was reduced to 
TNB with DTT immediately before the MTS modification assay (0.5 mol DTT per mol DTNB). 
Modification of TNB by MTS reagents was measured as a decrease in OD412 with a stopped-flow 
spectrophotometer as described (Karlin and Akabas, 1998, Meth. Enzymol 293, 123-145). The 
intrinsic rate of modification of NTB by MTSEA was 5-fold faster than by MTSES and was 27-fold 
faster than by MTSCE. 
 
The transition zone, comprised of loops from the LBD (loop 2, loop 9, and the 
Cys loop) and the TMD (pre-M1 sequence and M2-M3 linker), is positioned to 
convey structural rearrangements caused by agonist binding in the LBD to the 
channel gate in the TMD [Bouzat et al. 2004]. Therefore, we examined the effect of 
PNU-120596 on the rate of MTSEA modification at three reporter residues within the 
transition zone (E44C, N170C, and E172C), which is also a proposed site of 
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modulation by divalent cations [Galzi et al. 1996]. PNU-120596 reduced the rate of 
MTSEA modification at all three positions (Figure 3.5, Table 3.2). At N170C, PNU-
120596 decreased the accessibility of the substituted cysteine whereas ACh caused 
an increase.  The application of both compounds offset each other at N170C.  
Overall, the changes in cysteine accessibility in the transition zone caused by ACh 
and PNU-120596 were similar but not identical. 
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Figure 3.10: MTSCE modifies E44C at a slower rate than MTSEA, and ACh slows the rate of 
modification. n=3 for both data sets. The rate of modification by MTSCE in the absence of ACh (12.8 
M-1s-1) was 2,500-fold slower than by MTSEA (33,700 M-1s-1; Table 2). After adjusting for the faster 
intrinsic modification rate of MTSEA (Figure 3.9), the modification of E44C by MTSCE was 180-fold 
slower than by MTSEA, indicating a strongly negative electrostatic environment surrounding E44C. 
ACh slowed the modification of E44C by MTSCE 2.3-fold, whereas ACh slowed the modification by 
MTSEA 23-fold (Table 2). This difference suggests there are electrostatic differences in the 
unliganded and agonist-bound conformations.  
 
 
Interestingly, positive modulation of ACh-evoked currents by PNU-120596 
was lost in the E172C mutant (Table 3.1), but PNU-120596 still caused a decrease 
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in thiol accessibility at this position (Figure 3.5). One explanation is that the PNU-
120596 binding site includes E172, and the introduced cysteine (E172C) eliminates 
allosteric modulation but not binding. In this scenario, the observed reduction in the 
rate of MTSEA modification at E172C is due to physical occlusion by PNU-120596 
of the substituted cysteine at the putative binding site. An alternative explanation is 
that PNU-120596 binds to a site outside of the transition zone, away from E172, and 
the observed reduction in the rate of E172C modification is due to conformational 
changes induced there. In this scenario, the binding of PNU-120596 is unaffected 
and can still induce conformational changes, but the electrostatic coupling within the 
transition zone [Xiu et al. 2005] is sufficiently disrupted by the cysteine mutation that 
the induced conformational changes no longer enhance receptor gating. 
 Lastly, we examined the effect of ACh and PNU-120596 on the rate of 
MTSEA modification at two residues in the orthosteric site (W54 and W148) (Figure 
3.6). Structurally, these residues occupy two distinct locations within the agonist 
binding site. W148 is part of the principal subunit (Figure 3.1, yellow subunit). It 
lines the back wall of the agonist binding site and makes contact with agonists and 
competitive antagonists [Celie et al. 2004; Hansen et al. 2005]. W54 is part of the 
complimentary subunit and sits on the edge of the agonist binding site (Figure 3.1, 
cyan subunit) [Brejc et al. 2001]. ACh reduced the rate of MTSEA modification at 
these positions. In our interpretation, ACh reduces covalent modification at W148C 
by physically blocking access to the introduced cysteine. On the other hand, since 
carbamylcholine does not contact W54 [Celie et al. 2004], we hypothesize that ACh 
induces a short-range conformational change that makes W54C less accessible to 
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covalent modification. The ACh-dependent effect at W54C agrees with previously 
published work on wildtype α7 receptors [Gay et al. 2008]. PNU-120596 does not 
significantly affect the rate of MTSEA modification at W54C, but reduced the rate of 
MTSEA modification at W148C, suggesting that PNU-120596 induces allosteric 
conformational changes in the center of the agonist binding pocket, but not on the 
periphery.  
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Figure 3.11: MTSES modification of M40C is very slow. Responses following an exposure to 
MTSES (1 mM, 3 min) were not significantly different from the control responses (n=4). After MTSES 
exposure, subsequent exposure to MTSEA (1 mM, 3 min) caused a maximal inhibition as observed 
previously (McLaughlin et al., 2007), indicating that the cysteine thiol was not modified by the 
previous exposure to MTSES. Modification by MTSCE of M40C was also too slow to measure (not 
shown). Thus, the modification of M40C by anionic modifiers is dramatically slower than by the 
cationic MTSEA, indicating a strongly negative electrostatic environment around M40.   
 
 
Unexpectedly, we found that PNU-120596 was a full agonist of W148C 
receptor in C115A/L247T-containing α7 receptors (Figure 3.7A). One explanation is 
that the introduced cysteine allowed partial closure of the C-loop and lowered the 
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activation energy sufficiently to allow PNU-120596 to activate the receptor, while at 
the same time increased energetic barriers to ACh binding. The C-loop is a dynamic 
and flexible region that acts as a hinge of the orthosteric site [Hansen et al. 2005; 
Venkatachalan and Czajkowski 2008]. The EC50 for ACh-dependent activation of the 
W148C mutant receptor was increased ~100-fold (Table 3.1), as expected for a 
receptor with a mutation of an important aromatic residue of the agonist-binding 
pocket [Brejc et al. 2001]. We took advantage of this phenotype to test if PNU-
120596’s ability to alter cysteine accessibility was due to allostery or steric occlusion. 
Because ACh-evoked currents are more sensitive to covalent modification by 
different MTS reagents than PNU-evoked currents (Figure 3.7), we conclude that 
PNU-120596 induces conformational changes at this position through an allosteric 
mechanism. Consistant with this, a chemically-related PAM (NS-1738) does not 
affect equilibrium binding of [125I]α-bungarotoxin, also suggesting that it does not 
interact with the agonist binding site [Timmermann et al. 2007]. Recent work with 
chimeric α7 nAChR/5-HT3 receptors and mutagenic studies suggests a binding site 
in the transmembrane domain for PNU-120596 and LY-2087101 [Bertrand et al. 
2008; Young et al. 2008]. These data suggest that PNU-120596 and other 
modulators of α7 receptors bind at a conserved site within the transmembrane 
domain and cause conformational changes in the LBD to enhance gating of the 
receptor.  
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Table 3.3 - Comparison of α7 nAChR expression with and without RIC-3 
 
Mutant Without RIC-3 With RIC-3 
 EC50 (µM) Imax (µA) n EC50 (µM) Imax (µA) n 
M37C 4.5 ± 1.3 0.4 ± 0.12 10 5.2 ± 0.33 0.84 ± 0.06 3 
W148C N.R‡ - 4 205 ± 28 3.5 ± 0.52 11 
N170C 12 ± 1.0 0.11 ± 0.03 5 12 ± 1.4 1.3 ± 0.24 15 
E172C 39 ± 3.4 0.11 ± 0.02 5 
 
30 ± 2.0 0.7 ± 0.11 16 
 
‡ = No measurable response (up to 10 mM ACh) 
 
In the MWC model of allostery, positive allosteric modulators of ligand-gated 
ion channels enhance activation by stabilizing the protein in the open state. 
[Bertrand and Gopalakrishnan 2007]. Our results provide the first evidence that that 
PNU-120596 promotes activation of α7 receptors by causing some (but not all) of 
the same conformational changes in the LBD associated with agonists. We have 
previously shown that permeable divalent cations, which do not alter desensitization, 
also induce conformational changes in the LBD that are similar to those induced by 
agonists [McLaughlin et al. 2009]. Our work adds to a growing body of literature of 
both convergent and divergent conformational changes during gating of Cys-loop 
receptors [Chang and Weiss 2002; Pless et al. 2007; Sharkey and Czajkowski 
2008].  
Recent work suggests that the mechanisms of closed-to-open conformational 
changes induced by different agonists and of unliganded receptors are completely 
conserved regardless of the agonist applied; only the kinetics of the C-O transitions 
are affected [Purohit and Auerbach 2009].  While most of our data with PNU-120596 
agrees with this idea, modulation and rate measurements for the N170C mutant 
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seem to be an exception.  For this mutant, PNU-120596 slows the rate of 
modification while ACh increases it (Figure 3.5). Thus, each ligand stabilizes a 
population of conformational intermediates that are distinct from each other and from 
the resting unliganded state(s). A model in which C-O transitions occur via a single 
pathway, where agonists and PAMs can only change the forward or reverse rates 
(Figure 1.5), would predict that PNU-120596 and ACh would cause similar changes 
in accessibility at all residues. Our results conclusively show that PNU-120596 can 
alter the α7 receptor in the absence of the C-O gating transition (Figure 3.4-3.6). If 
there is a single path, then the observation that PNU-120596 causes a change in 
accessibility of N170C opposite to that caused by ACh suggests that the receptor 
would be stabilized in closed intermediate states further away from the open state, 
and PNU-120596 would be unable to enhance the conserved C-O transition. But 
PNU-120596 still acts as a positive allosteric modulator of N170C receptors, 
suggesting that PNU-120596 induces conformational changes along alternative 
pathways that lower energetic barriers to activation and lead to positive modulation. 
The differences between the conformational intermediates induced by PNU-120596 
and those induced by ACh are likely to be subtle, as they are not as apparent at 
other cysteine mutants.  
In conclusion, we have shown that PNU-120596 and ACh induce a set of 
overlapping structural transitions in the extracellular ligand-binding domain. Our 
results indicate that PAMs such as PNU-120596 enhance gating of ligand-gated ion 
channels by inducing some of the same structural transitions caused by agonists.  In 
addition, we have identified mutations in the transition zone that eliminate 
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modulation of α7 nicotinic receptors by PNU-120596 via decoupling between the 
LBD and TMD. We have provided evidence that PNU-120596 does not bind to 
unoccupied agonist-binding site(s).  The PAM-induced changes in receptor kinetics, 
while not usually sufficient to activate receptors, would lower the energy barriers to 
agonist-induced activation by both enhancing the agonist-evoked C-O transitions 
and unique transitions. This process would “prime” the receptors to undergo a gating 
transition, allowing more of the energy of agonist binding to drive changes in the 
conformational equilibrium towards activation [Jackson 1989].
  
 
 
 
CHAPTER 4 
 
 
 
 
 
PERMEABLE DIVALENT CATIONS AND ACETYLCHOLINE CAUSE 
SIMILAR GATING TRANSITIONS IN THE EXTRACELLULAR 
LIGAND-BINDING DOMAIN OF THE α7 NICOTINIC RECEPTOR  
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Introduction 
 Allosteric modulation of membrane receptors is increasingly recognized as a 
common mechanism used to control cellular signal transduction [Lena and 
Changeux 1993; Gao and Jacobson 2006]. In general, allosteric modulator binding 
causes changes in the response of the receptor to the "native ligand", presumably 
by altering the energetic barrier between resting and activated conformations. In 
most cases the modulator does not activate the target receptor in the absence of 
agonist. While there has been substantial progress in identifying the binding sites for 
many allosteric modulators (for example, [Sigel 2002]), the mechanisms by which 
modulators induce their effects remain poorly defined.   
 Some of the best examples of allosteric modulation involve members of the Cys-
loop family of ligand-gated ion channels that includes nAChRs as well as the 
GABAA, glycine, and 5-hydroxytryptamine-3 receptors [Changeux and Taly 2008]. 
Cys-loop receptors transduce the energy of agonist binding into conformational 
changes that lead to channel opening [Sine 2002]. All family members share a 
similar structure: they are transmembrane proteins assembled from five homologous 
or identical subunits.  Each of these subunits is comprised of a large amino terminal 
extracellular domain (LBD), a large intracellular loop, and a four α-helix bundle 
forming a transmembrane domain (TMD).  Recent studies aimed at identifying the 
structural basis for ligand gating have focused on the "transition zone" [Gay and 
Yakel 2007] a region of the receptor at the boundary between the LBD the TMD.  
The transition zone includes structural elements thought to link the TMD and the 
ligand binding site [Lee and Sine 2005; Lummis et al. 2005; Mukhtasimova et al. 
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2005]. While the evidence for this linkage is preliminary, a number of experimental 
approaches have unequivocally mapped the site for ligand binding to the interface of 
adjacent subunit LBDs [Sine 2002].  More recently, the crystal structures of ACh-
binding proteins (AChBPs) from Lymnea, Aplysia, and Bulinus [Brejc et al. 2001; 
Celie et al. 2004; Celie et al. 2005] have provided a structural context for these 
biochemical and functional studies.  The AChBPs are soluble proteins that act as 
ACh buffers in invertebrates [Smit et al. 2001]; they share both sequence and 
functional homology to the LBD of Cys-loop receptors.  Recently, two structures of 
homologous bacterial ligand-gated ion channels were added to the structural 
database of Cys-loop receptors [Hilf and Dutzler 2008; Bocquet et al. 2009; Hilf and 
Dutzler 2009]. These crystal structures have been used to develop and refine 
homology models of Cys-loop receptors [Le Novere et al. 2002; Unwin 2005].  Our 
goal is to use these refined models to test specific mechanistic hypotheses that 
attempt to explain the dynamics of both ligand-induced receptor activation and 
allosteric modulation [Kash et al. 2003; Lee and Sine 2005; Lummis et al. 2005; 
Mukhtasimova et al. 2005].  
 Many neuronal nAChRs exhibit positive allosteric modulation by physiological 
concentrations of Ca2+ [Mulle et al. 1992; Vernino et al. 1992]. In α7 nAChRs (but 
not other nAChRs) Ba2+ or Sr2+ can elicit effects similar to Ca2+ [Vernino et al. 1992; 
Galzi et al. 1996; Eddins et al. 2002a; Eddins et al. 2002b].  This modulation 
consists of an increase in both the efficacy and the potency of ACh.  The functional 
effects of divalents are similar to those caused by an emerging class of nicotinic 
modulating drugs collectively referred to as PAMs (positive allosteric modulators; 
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[Dani and Bertrand 2007]). Thus one rationale for a mechanistic characterization of 
divalent modulation of α7 nAChRs is to serve as a model for studies of drugs such 
as PAMs developed to elicit a similar effect.  
  Previous studies demonstrated that the modulation of α7 nAChRs by divalent 
cations is independent of divalent cation permeation, suggesting that the binding site 
for modulation is extracellular [Eddins et al. 2002b].  In addition, several studies 
have demonstrated the importance of conserved LBD glutamate residues (E44 and 
E172 in chick α7) in divalent cation modulation, and it has been suggested that 
these may form the allosteric modulation-binding site [Galzi et al. 1996; Le Novere 
et al. 2002; Lyford et al. 2003]. In this paper, we tested the hypothesis that 
conformational changes evoked by divalent cation modulators of the α7 receptor are 
similar to those evoked by ACh.   In addition, we examined whether E44 and E172 
are required for divalent cation-evoked conformational changes. We found some 
similarities between Ba2+ evoked conformational changes and those caused by 
ACh. Surprisingly, we also found that the effects Ba2+ on modification rates did not 
require E44 or E172, suggesting that these residues do not form the divalent cation 
binding site. 
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Results 
The substituted cysteine accessibility method (SCAM) is an established 
experimental approach to examine protein conformational dynamics [Karlin and 
Akabas 1998]. We previously used this approach to scan regions of the chick α7 
receptor and identified residues where the rates of thiol-specific modification by 
MTSEA were altered by ACh [Lyford et al. 2003; McLaughlin et al. 2007]. We 
consider two alternative mechanisms for ACh-dependent effects on modification 
rates. If the substituted cysteine is at a position that is part of the agonist binding site 
[Sine 2002], than the effect of ACh could be due to steric occlusion.  Alternatively, if 
the substituted cysteine is not near the binding site, than we infer that a change in 
modification rates is a result of conformational or electrostatic change induced by 
agonist-dependent activation. In this way, these residues serve as reporters of 
intramolecular changes during receptor activation.   
SCAM can be used in the same way to identify conformational changes caused 
by allosteric modulators.  Figure 4.1 shows a representation of the region of the α7 
receptor LBD targeted in this study.  A discrete region of the inner β sheet, including 
M37, M40, and N52 was initially chosen to examine the effects of the divalent cation 
Ba2+ on MTSEA modification rates.  We also examined the effects of Ba2+ at 
transition zone residues previously implicated in modulation by divalent cations, 
including E44, E172, as well as an adjacent position N170.  All of the cysteine 
replacements at these residues have previously been shown to exhibit agonist-
sensitive MTSEA modification rates, allowing us a basis for comparison for the 
effects of Ba2+.  
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For these studies we began by confirming the modulatory effects of Ba2+ on 
ACh-dependent activation of our parental phenotype, containing the C115A/L247T 
mutations. Wild-type α7 nAChRs exhibit a complex positive modulation by divalent 
cations such as Ca2+ or Ba2+ that includes increases in both efficacy and potency 
[Galzi et al. 1996].  In contrast, receptors with the L247T phenotype typically exhibit 
a simplified modulatory response consisting only of a 5- to 10-fold left shift in the 
ACh dose-response. The C115 position is the only accessible cysteine in the LBD, 
and mutation to C115A simplifies our interpretation of MTSEA modification at 
introduced cysteines.  
Figure 4.2A shows the effect of 10 mM Ba2+ on the α7 C115A/L247T receptor. 
There was a leftward shift in the dose-response curve corresponding to a ~ 10-fold 
decrease in EC50 (increase in potency).  Of note, we do not see an effect of Ba2+ on 
efficacy in the parental background. We suspect this is due to the higher gating 
constant of receptors with the L247T mutation.  Figure 4.2B shows that modulation 
by Ba2+ was eliminated in the E44C mutant, confirming that this conserved 
glutamate is required for Ba2+ binding or allosteric coupling of Ba2+ binding to ACh-
dependent activation.  This result is similar to the effect of an E44Q mutant 
described in wild type and L247T α7 nAChRs [Galzi et al. 1996; Eddins et al. 2002b].  
Table 4.1 provides a compilation of EC50's, modulatory effects of 10 mM Ba2+, and 
the maximal responses of the mutants described in this report.  Neither of the 
transition zone glutamate mutants (E44C and E172C) exhibited a positive 
modulation, while the N52C mutant displayed a high partial agonism by Ba2+ in the 
absence of ACh.  
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Figure 4.1: A model of the α7 AChR extracellular domain.  Ribbon cartoon showing two of the five 
subunits viewed from the outside.  In the subunit to the left of the central interface (yellow), the outer 
β sheet in is highlighted in orange, the transition zone E44 residue is orange, and the W148 residue is 
shown in gray to identify the ACh binding pocket [Zhong et al. 1998]. The subunit to the right shows a 
view of the inner sheet (teal), and other residues targeted in this study. The sequence surround 
mutants characterized in this study is shown beneath the cartoon: M37, M40 cyan; N52 green; N170 
blue; E172 purple.   
 
Previously, we measured the effects of ACh on reactivity of cysteine mutants in 
the inner β sheet of the chick α7 nAChR [McLaughlin et al. 2006]. Several residues 
(M37C, M40C, and N52C) exhibited a change MTSEA reaction rates in the 
presence of ACh. We interpret differences in modification rates in the absence or 
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presence of ACh to reflect differences in the apparent accessibility of the introduced 
cysteine between the unliganded and liganded states.  To test if these sites could 
also be used as reporters of allosteric modulator-induced conformational change we 
examined the effects of Ba2+ on rates of MTSEA modification. 
 Figure 4.3 shows an example of the protocol used to measure the thiol 
modification rate of the receptors with the M37C mutation. ACh-evoked current 
amplitudes decreased following brief, repeated exposure to a limiting concentration 
of MTSEA (5 µM, 15 seconds). To ensure that the modification reactions were 
complete, all rate measurements included a final prolonged application of ~100-fold 
higher concentrations of MTSEA (Fig. 4.3A and 4.3B, right). Currents measured 
following this application represent the endpoint of the reaction between MTSEA 
and receptors.  When the same protocol included Ba2+ pretreatment and co-
application with MTSEA (see Methods), the decreases in current amplitudes were 
slowed but the same endpoint was obtained (Fig. 4.3B).  Normalized current 
amplitudes were plotted as a function of the cumulative time of exposure to MTSEA, 
and pseudo first-order rates were extracted from the single-exponential fits (Fig. 
4.3C).  We observe a significant decrease in the MTSEA modification rate for M37C 
(Fig. 4.4) in the presence of 10 mM Ba2+, demonstrating that this modulator caused 
changes in the conformation or electrostatic environment around the M37C side 
chain.   
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Table 4.1 - Effects of Ba2+ on ACh evoked currents.  
mutant ACh  EC50, µM (n) ACh Imax 
µA 
Ba2+ 
efficacya 
 control + 10 mM   Ba2+    
C115A/L247
T 1.8 ± 0.4 0.17 ± 0.02 4 6.9 0.1 
M37C 2.0 ± 0.5 0.35 ± 0.12 4 0.92 0.2 
M40C 7.7 ± 1.1 1.1 ± 0.1 5 3.0 0.1 
N52C 2.6 ± 1.3 ndb 5 0.34 0.6 
E44C 7.8 ± 0.4 10.1 ± 0.4 4 5.4 0.01 
N170Cc 13 ± 1.7 2.1 ± 0.4 6 1.7 0.03 
E172Cc 30 ± 2.7 50 ± 9.2 4 1.3 0.02 
M40C/E172
Qc 85 ± 6.2 134 ± 11 5 0.7 0.02 
 
ACh dose-response measurements in the absence or presence of Ba2+.  EC50 estimates are 
mean values  ± S.E.M. (a)   Ba2+ efficacy is the fraction of maximal ACh-evoked current that is 
evoked by 10 mM Ba2+ in the absence of ACh.  (b) nd: not determined because Ba2+ was a strong 
partial agonist.  (c)  Mutants studied using co-expression with human RIC-3 (Halevi et al., 2002).   
 
Using the protocol described in Figure 4.3, we determined second-order rate 
constants for modification of the three reporter residues in the inner β sheet (M37C, 
M40C, and N52C).  Figure 4.4A shows mean values of the rate constants 
measured in the presence of MTSEA alone, MTSEA plus ACh, and MTSEA plus 
Ba2+.  We observed significant decreases in reaction rates of both M37C and M40C in 
the presence of 10 mM Ba2+.  The effects are quantitatively similar to those 
measured in the presence of ACh [McLaughlin et al. 2006], consistent with the idea 
that Ba2+ causes conformational changes similar to those induced by agonist in this 
  86 
region of the α7 nAChR.   To more directly compare the effects of ACh and Ba2+ on 
reaction rates, we plot rate constants as ratios in Figure 4.4B. This figure highlights 
the differences in MTSEA rates under different conditions at these three positions.  
In contrast to M37C and M40C, we observed no significant effect of Ba2+ on MTSEA 
modification rate of N52C. This result parallels our previous study in which we found 
the effect of ACh on MTSEA modification rate of N52C was also different from that 
of neighboring residues M37C and M40C. Collectively, these results suggest that 
divalent cations such as Ba2+ act to promote some, but not all, of the conformational 
or electrostatic changes elicited by ACh.  While ACh acts to stabilize the open state, 
Ba2+ acts to stabilize a state (or states) that are energetic intermediates between 
closed and open channels.   
 
Figure 4.2: Positive allosteric modulation by divalent cations requires E44. ACh dose-
response curves for the parental C115A/L247T (A) and the E44C mutant (B) in the absence (open 
squares) and presence (filled squares) of 10 mM BaCl2. Data are fitted to the Hill equation (solid 
lines). The positive allosteric modulation (leftward shift in the dose response curve) typically exhibited 
by α7 nAChRs (A) is lost in the E44C mutant (B). Data are mean values (± S.E.M.) from three 
determinations, normalized to the maximal value of the Hill equation fit of each data set. Hill 
coefficients for C115A/L247T (A): 2.5±0.2 (open squares, -Ba2+), 1.9±0.4 (filled squares, +Ba2+); and 
for the E44C mutant (B) 1.7±0.2 (open squares, -Ba2+), 2.9±0.7 (filled squares, +Ba2+). 
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Figure 4.3: Barium slows the rate of MTSEA modification at M37C. Example of experimental 
paradigm used to assess Ba2+ effects on modification rates.  (A) Successive ACh-evoked current 
traces recorded before and after repeated exposures to MTSEA (5 µM, 15 seconds), showing a 
decrement in responses to 30 µM ACh.  Endpoints of MTSEA modification are determined by 
prolonged application of 500 µM MTSEA (right). (B) The same protocol, including Ba2+ pretreatment 
and co-application with MTSEA. Current traces are truncated in both (A) and (B) between 
consecutive MTSEA applications; in all cases the currents were allowed to return to baseline prior to 
the next application of MTSEA ± ACh. (C) Peak current amplitudes from (A) and (B) are normalized 
and plotted versus total MTSEA exposure time.  Data from this single experiment (no error bars) are 
fitted to a single-exponential decay (solid line) to extract an apparent pseudo first-order rate constant.  
The pseudo first-order rate constants calculated in this experiment were 0.011 s-1 and 0.0019 s-1 for 
control (A) and +Ba2+ (B) measurements, respectively. Second-order rate constants are calculated 
from these values (Figures 4-6; Table 4.2). 
 
Modulation by divalent cations is known to require the conserved acidic residues 
at E44 and E172 [Karlin and Akabas 1998; Lyford et al. 2003].  We next tested 
whether Ba2+ could cause changes in the rates of MTSEA modification at E44C, 
N170C, and E172C.  Similar to residues in the inner β sheet, each of these mutants 
has been shown to be a reporter of conformational or electrostatic changes induced 
by ACh [Lyford et al. 2003; McLaughlin et al. 2007]. Figure 4.5A shows mean 
values of second order rate constants measured in the presence of MTSEA alone, 
MTSEA plus ACh, and MTSEA plus Ba2+.  At N170C, a mutant that showed 
allosteric modulation (Table 4.1), the rate of MTSEA modification in the presence of 
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Ba2+ was the same as that measured in MTSEA alone, but was different from that 
measured in the presence of ACh. This observation suggests that conformational or 
electrostatic changes induced by modulators at this residue are distinct from those 
induced by ACh.  Differences between the effects of ACh and Ba2+ were most 
pronounced at E44C; at this residue, the modification rate was ~10 fold higher in the 
presence of Ba2+ compared to that measured in the presence of ACh (Figure 4.5B). 
Surprisingly, despite the fact that both E44C and E172C show no positive allosteric 
modulation of ACh currents by Ba2+ (Fig. 4.2, Table 4.1),  both exhibited significant 
Ba2+-dependent decreases in MTSEA modification rate.  
 The hypothesized requirement for E44 and E172 in divalent cation modulation 
was based upon studies of charge neutralization mutants (E44Q, E172Q) in which 
modulation was lost.  From these and other studies, both residues were proposed to 
be participants in a binding site which mediates the divalent cation allosterism [Galzi 
et al. 1996; Eddins et al. 2002b].  The loss of Ba2+ dependent modulation in E44C or 
E172C mutations (also charge neutralization mutations) is consistent with this 
proposal, but the effects of Ba2+ on MTSEA modification rates are not.  One possible 
explanation for these observations is that Cys replacements at E44 and E172 do not 
prevent Ba2+ binding, but cause an uncoupling of binding and allosteric modulation.  
If Ba2+ binds near E44C and E172C, the slowed modification rate at E44C or E172C 
would be explained by physical occlusion of the thiol side-chain by bound Ba2+.   
  89 
 
Figure 4.4: Barium alters the rate of MTSEA modification at inner β sheet residues. (A) Using 
the protocol described in Figure 3, we determined second-order rate constants for three reporter 
residues in the α7 nAChR inner β sheet (M37C, M40C, and N52C).  Mean values for second-order 
rate constants for modification by MTSEA alone (control), MTSEA + ACh, and MTSEA + Ba2+ are 
shown. * Rate was significantly different from control (P<0.05).  (B) A plot of the ratios of second-
order rate constants.  Ba2+ and ACh both slowed the rates of modification of M37C and M40C. At 
N52C, however, the rate of modification in the presence of Ba2+ was not significantly different from 
control, while ACh accelerated the modification rate.  See Table 4.2 for summary including (n) for 
each condition. 
 
 Alternatively, the glutamates could be a required component in the transduction 
pathway between Ba2+ binding and receptor modulation, but are not direct 
participants in the binding site. In this case divalent cations bind at a different site 
and elicit conformational or electrostatic changes (detected as changes in E44C and 
E172C modification rates), but binding does not lead to modulation.  To test this 
possibility we examined MTSEA modification rates at M40C α7 nAChRs in which a 
second, charge-neutralizing mutation (E172Q) was introduced.  We reasoned that if 
E172 is required for binding of divalent cations, than the modification rate of M40C 
should be insensitive to Ba2+. If, however, Ba2+ binds to the receptor and causes 
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conformational changes, despite the mutation at E172, this would be reflected by 
changes in the rate of modification of M40C. 
  
Figure 4.5: Barium alters the rate of MTSEA modification at residues required for 
modulation by divalent cations. Second-order rate constants were measured for three residues in 
the "transition zone" of the α7 nAChR (E44C, N170C, and E172C).  (A) Mean values for second-
order rate constants for modification by MTSEA alone, MTSEA + ACh, and MTSEA + Ba2+.  Ba2+ 
caused a significant decrease in MTSEA modification rates of both E44C and E172C, despite the loss 
of divalent cation-dependent modulation. Ba2+ did not have a significant effect on the modification 
rate of N170C, although ACh significantly increased the rate of modification of this residue. *Rate 
was significantly different from control (P<0.05). ‡Rate was significantly different from that obtained in 
presence of ACh (P<0.05). The plot of rate constant ratios (B) shows that the effect of Ba2+ on the 
rate of modification of E44C was significantly less than the effect of ACh.  See Table 4.2 for summary 
including (n) for each condition.   
 
We measured dose-response relationships for the M40C/E172Q double mutant 
in the absence and presence of 10 mM Ba2+ and confirmed that it was not  positively 
modulated by Ba2+ (Table 4.1).  When the rates of MTSEA modification of the M40C 
in this background were measured, we found that Ba2+ caused a significant slowing 
of MTSEA modification rate (Figure 4.6).  The modification rates of M40C were 
independent of the E172 mutation. This result suggests that the binding site for Ba2+ 
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modulation is somewhere other than a site which includes E44 and E172 in the α7 
nAChR transition zone [Le Novere et al. 2002].  
 
Figure 4.6: Charge neutralization at E172 does not alter the rate of modification M40C by 
MTSEA. Mean values for second-order modification rate constants for M40C (left, data from Fig. 3) 
compared to those obtained in receptors containing the E172Q mutation (M40C/E172Q). *Rates 
were significantly different from control (P<0.05).  See Table 2 for summary, including (n) for each 
condition.  
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Discussion 
The mechanisms of protein allosterism have been the subject of exhaustive 
modeling and model refinement since studies of Monod, Wyman and Changeux 
[Monod et al. 1965] and those of Koshland and colleagues [Koshland et al. 1966]. In 
the nicotinic receptors, several different types of allosteric behavior have been 
described. The concerted, or MWC model, for example, refers to the allosteric effect 
of ligand binding on channel opening; this model suggested that binding of multiple 
agonists acted in concert to yield their “at a distance” effect. Experimental tests of 
the MWC model with combinations of agonists and antagonists suggest that a 
stepwise process more accurately describes the activation process [Prince and Sine 
1999; Krauss et al. 2000].  
Another type of allosterism seen in some nicotinic receptors is the positive 
allosteric modulation by divalents such as Ca2+ or Ba2+ [Vernino et al. 1992; Galzi et 
al. 1996]. For this type of allosterism, a fundamental question is whether the 
modulation alters the conformational “pathway” from closed to open states or simply 
modifies the kinetics of an agonist-dependent closed to open transition. Few studies 
have attempted to address this question, but a recent report does examine the 
conformational effects of positive allosteric modulators (benzodiazepines) in GABAA 
receptors [Sharkey and Czajkowski 2008]. This study used SCAM to show that a 
prominent effect of benzodiazepines is to increase the access of GABA to its binding 
site, reducing the energetic barrier to the initial step in receptor activation, GABA 
association.  Divalent cation effects on α7 nAChRs provide a similar paradigm in 
which to examine the conformational changes evoked by allosteric modulators.  
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In an earlier report we described an α7 nAChR mutant with a pair of cysteine 
substitutions positioned to introduce a disulfide bond in the outer β sheet 
[McLaughlin et al. 2006].  In our parental background this mutant was fully activated 
by divalent cations in the absence of ACh, but when expressed in an α7 nAChR 
without the L247T mutation it required both ACh and divalent cations for channel 
activation.  If we assume that activation of this mutant occurs because of Ba2+ 
interaction with the divalent cation allosteric site, then it suggests that Ba2+ and ACh 
promote two overlapping but distinct sets conformational changes. The experiments 
presented in this report provide further evidence that conformational effects of 
divalent cations are similar to those elicited by ACh. Thus the simplest interpretation 
of our data is that divalent cations act by enhancing transitions in an ACh-dependent 
activation pathway without substantial effect on the final closed to open transition.   
  
 Le Novere and colleagues [Le Novere et al. 2002] proposed a model for a 
divalent cation binding site that was based on earlier experiments, homology 
between the α7 nAChR LBD and the Lymnea AChBP, and the known database of 
divalent cation binding proteins [Galzi et al. 1996; Brejc et al. 2001].  The focus of 
this model was a cluster of 4 negatively charged residues in the transition zone: 
D41, D43, E44, and E172. Mutational analysis suggested that the glutamate 
residues were critical, since charge neutralization at either of the aspartate residues 
had only modest effects on divalent modulation.  While the geometry of these 
residues in models of the LBD is consistent with their proposed model, our results 
with Ba2+-induced conformational changes are not.  A mutation of either E44 or 
E172 to cysteine eliminates the modulation, but not the conformational changes 
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associated with Ba2+ modulation.  This strongly suggests that the allosteric effects of 
Ba2+ are “transmitted” in a conformational pathway that requires these glutamates 
for some role other than divalent cation binding.  It is unlikely that the Cys 
substitution is able to act as a functional substitute for Glu in a divalent cation site: a 
survey of all known Ca2+ binding sites found that Cys was never a contributor to a 
Ca2+ co-ordination site, while it often plays this role in Zn2+ binding sites [Harding 
2004].  Other possible candidates for a divalent cation modulation site in the α7 LBD 
include acidic residues in β6 and β8, which may combine with neighboring carbonyl 
groups to form a site for divalent cation binding.  Alternatively, the recent work of 
Horn and colleagues [Santarelli et al. 2007] has demonstrated that aromatic 
residues may provide the negative electrostatic environment required for formation 
of a physiologically relevant divalent cation binding site through the π-cation-type 
interactions.  This is the same structural motif that has been shown to provide the 
negative electrostatic environment in the cholinergic agonist binding site [Zhong et 
al. 1998]. 
 In summary, we have shown that the permeable divalent cation Ba2+ induces 
similar conformational changes as the agonist ACh in the extracellular-ligand 
binding domain of the α7 nAChR. The next section of this dissertation will introduce 
new methodologies to determine what those specific mechanisms are.  
  
  95 
Table 4.2 - Summary of MTSEA modification data.   
 
MUTANT MTSEA   modification rate  x    103, M-1 S-1 (n) 
          control + ACh  + Ba2+ 
M37C 2.4 ± .03  (10) 0.30 ± 0.05 (4) 0.40 ± 0.02 (5) 
M40C 16 ±  0.2  (13) 2.2 ± 0.4 (3) 2.8 ± 0.05 (7) 
N52C 0.40 ± .08  (9) 1.4 ± 0.04 (7) 0.26 ± 0.02 (7) 
    
E44C 23 ± 0.7  (4) 0.90 ± 0.05 (4) 9.3 ± 0.1(8) 
N170Ca 3.3 ± .05  (7) 5.7 ± 0.1 (7) 3.7 ± 0.06 (9) 
E172Ca 15 ±  0.4  (5) 3.5 ± 0.1 (5) 7.3 ± 0.3 (6) 
    
M40C/E172Qa 14 ± 0.5  (5) 1.3 ± 0.1 (5) 2.0 ± 0.3 (6) 
 
Second-order rate constants ± S.E.M. for various conditions at each Cys mutant. (n), 
number of determinations. (a) Mutants studied using co-expression with human RIC-
3 (Halevi et al., 2002).   
 
  
 
CHAPTER 5 
 
 
HOMOLOGY MODELS OF THE α7 RECEPTOR DERIVED FROM 
BACTERIAL CYS-LOOP RECEPTORS  
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Introduction 
 
 Nicotinic acetylcholine receptors (nAChRs) are the prototypical member of 
the Cys-loop family of ligand-gated ion channels that also includes GABAA, 
serotonin type 3, and glycine receptors. This family of receptors assembles as 
heteromeric or homomeric pentamers around a central pore. Each subunit contains 
an extracellular ligand-binding domain, an α-helical transmembrane domain, and an 
intracellular domain. 
 The crystallization of the Lymnaea Acetylcholine Binding Protein (AChBP) 
provided a wealth of information regarding the ligand-binding site of Cys-loop 
ionotropic receptors [Brejc et al. 2001]. Subsequently, the Aplysia AChBP was 
discovered and structures have been solved for proteins in the presence of various 
agonists, antagonists, and allosteric modulators [Hansen et al. 2002; Celie et al. 
2004; Celie et al. 2005; Hansen et al. 2005; Hansen and Taylor 2007]. Information 
from these structures as well as a combination of functional and computer modeling 
have shown that movement of the C-loop towards bound agonist is one of the first 
conformational changes associated with gating of Cys-loop receptors [Szarecka et 
al. 2007; Venkatachalan and Czajkowski 2008].  This rearrangement at the agonist-
binding site is followed by additional conformational changes that converge on the 
channel gate in the pore-lining M2 helices [Gay and Yakel 2007]. However, the 
AChBP lacks the ion-conducting transmembrane domain and cannot provide a 
complete picture of the structure and conformational changes of this family of 
ionotropic receptors.  
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 One approach to this problem has been to develop hybrid homology models, 
consisting of a fusion of the AChBP structures to cryo-EM images of the 
transmembrane domain of Torpedo nAChR [Miyazawa et al. 1999; Taly et al. 2005; 
Unwin 2005]. However the 4Å resolution of the ion-conducting domain was refined 
computationally and is not a de novo structure, which limits a detailed analysis of  
receptor gating at the atomic level.  Another limitation of the Torpedo nAChR model 
is that electrophysiological data does not support the rigid-body rotation model of 
gating for this receptor [Miyazawa et al. 2003; Cymes et al. 2005; Cymes and 
Grosman 2008]. Accordingly, the validation of computational (in silico) studies with 
electrophysiological data is crucial for eludicating the gating mechanisms of the Cys-
loop family of receptors.  
 To address these limitations, we have developed homology models of the α7 
nicotinic receptor in the closed and open states, based on the full-length, high-
resolution structures of bacterial Cys-loop receptors [Hilf and Dutzler 2008; Bocquet 
et al. 2009; Hilf and Dutzler 2009]. We have validated these models using 
computational and electrophysiological data, and address the utility and limitations 
of these models to study receptor gating. We find that changes in electrostatics are 
a better predictor of MTSEA accessibility in the LBD than solvent accessibility. Our 
long-term goal is to use these homology models for molecular dynamics simulations 
to identify mechanisms of gating of the α7 nicotinic receptor.  
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Results 
 Homology models of the α7 nicotinic receptor generated from the closed state 
structure (ELIC) [Hilf and Dutzler 2008] and open state structure (GLIC) [Bocquet et 
al. 2009] are shown in Figure 5.1-5.2. Qualitatively, both models retain the 
secondary structure of the Cys-loop receptor family, including a perpendicular beta 
sheet array in the extracellular domain, and a bundle of four transmembrane helices.  
Both models show a tilting of the pore-lining M2 helix from the closed to the open 
state, which is thought to be an important for channel gating (Figure 5.3) [Hilf and 
Dutzler 2009]. An important difference between our models and the existing AChBP 
structures is that ELIC and GLIC lack the aromatic residues that are required for 
binding of cholinergic ligands [Hilf and Dutzler 2008; Bocquet et al. 2009]. As a 
result, the ligand-binding residues of the α7 homology models are oriented such that 
the agonist-binding site cannot accommodate cholinergic ligands (Figure 5.4). 
Another limitation is that GLIC receptor, does not desensitize even when maximally 
activated by acidic pH [Bocquet et al. 2007], whereas α7 nAChR  is inhibited by 
acidic pH and quickly desensitizes10. 
 The strength of these new homology models is not in providing additional 
details about the agonist-binding site. There is a wealth of structural and 
pharmacological data on the agonist-binding site from the AChBPs [Brejc et al. 
2001; Celie et al. 2004; Hansen et al. 2004]. Rather, these new homology models 
are useful because they provide a higher resolution picture of the transmembrane 
domain, with the extracellular and transmembrane domains coupled in a full-length 
                                                 
10
 Barron SC and McLaughlin JT, unpublished observations that α7 receptors are inhibited by protons. There is 
precedent for acidic pH enhancing and inhibiting β2* ,  β4*  nAChRs and GABAARs [Abdrakhmanova et al. 
2004; Wilkins et al. 2005]. 
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receptor. The loops that connect the extracellular and transmembrane domains are 
critical for the function of Cys-loop receptors [Xiu et al. 2005; Hanek et al. 2008]. 
Additionally, loop 2, loop 9, and the Cys-loop from the AChBP cannot form 
functional chimeric channel when fused with the 5-HT3A receptor; replacement of the 
AChBP sequence with that of the 5-HT3A  for these three loops is required [Bouzat et 
al. 2004]. These models can be used to study to conformational changes that occur 
downstream of the agonist-binding site, which lead to gating and an increase in ion 
conduction.  
 
Figure 5.1: α7 homology model in the closed (non-conducting) state. The entire pentameric 
model is shown in (A). An overlay of the α7 model (green) with the ELIC starting structure (blue) is 
shown in (B). 
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 Three independent techniques were used to evaluate the quality of the 
homology models. For the closed and open state model, the template structure 
(ELIC and GLIC, respectively) was overlaid with the corresponding homology model, 
as shown in Figure 5.1B and 5.2B. The RMSD was calculated between the 
respective template structure and homology model, to determine the average atomic 
distances [Maiorov and Crippen 1994].  The RMSD for backbone carbons in the 
closed state model was 1.2 Å, and 1.1 Å for the open state model, suggesting the 
structural sequence alignment and locations of inserted and deleted sequence 
retained the secondary structure of the bacterial Cys-loop receptors in the homology 
models.  
 Secondly, a Profiles 3D self-compatibility score based on the compatibility of 
each amino acid with its surrounding environment was generated [Luthy et al. 1992]. 
The Profiles 3D algorithms reduces the three-dimensional structure of a protein into 
a one dimensional score; this score is calculated based on eighteen environmental 
classes that account for the fraction of the side chain that is solvent exposed, side 
chain polarity, and the local secondary structure [Bowie et al. 1991].  The one-
dimensional score is then aligned with the amino acid sequence of the protein based 
on a 3D-1D scoring matrix, creating a Profiles 3D score11. For the closed state 
model, the Profiles 3D score was 493 with an acceptable range of 312-691. For the 
open state model, the Profiles 3D score was 605 with an acceptable range of 329-
729. The Profiles 3D score was further analyzed by plotting the individual scores for 
each residue (Figure 5.5) for the homology models and their respective starting 
                                                 
11
 The 3D-1D scoring matrix measures the compatibility of the twenty amino acids with the eighteen possible 
environmental classes. A higher score represents a higher compatibility between the amino acid and the local 
environment [Bowie et al. 1991; Luthy et al. 1991]. 
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structures. The M4 helix has the lowest Profiles 3D score among ELIC and GLIC 
structures, meaning that the fit of the original x-ray diffraction data to the three-
dimensional model was poor. Not surprisingly, the M4 helix also has the lowest 
Profiles 3D score in the corresponding closed state and open state homology 
models. The closed state model has a poorer fit in the first 100 residues for four of 
the five subunits relative to the ELIC structure. This region corresponds to the β1, 
β2, β6, Loop 2, and the A Loop of the ligand-binding domain, suggesting that the fit 
of the closed state homology model to these regions of the α7 nAChR is not as good 
as the starting structure. The Profiles 3D scores of the open state model very closely 
match those of the GLIC structure, which may be the result of the higher resolution 
of GLIC compared to ELIC (2.8 Å vs. 3.3 Å, respectively). The numerical and plotted 
Profiles 3D score show that the internal residue compatibility of the closed and open 
state models closely match their respective bacterial Cys-loop receptor template.  
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Figure 5.2: α7 homology model in the open (ion conducting) state. The entire pentameric model 
is shown in (A). An overlay of the α7 model (red) with the GLIC starting structure (yellow) is shown in 
(B). 
  
 Figure 5.6 and 5.7 shows stereochemical validation experiments, carried out 
with Procheck [Laskowski et al. 1993]. Specific parameters for bond length, bond 
angles, and energetics are conserved within a narrow range for all protein structures 
found in the PDB databank [Morris et al. 1992]. Homology models and de novo 
structures can be analyzed against the existing data set to look for gross distortions 
in amino acid stereochemistry. A limitation of this analysis is that good 
stereochemistry does not necessarily indicate a well-fit homology model, as these 
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parameters can be tightly constrained during energy minimization. To circumvent 
this limitation, the closed and open state models were energy minimized in a simple 
two-step process.  
 
Figure 5.3: Top down view of the α7 homology models. The closed model is shown in (A), and 
the open model is shown in (B). Both views are from the extracellular side looking down the ion 
conduction pathway. 
 Procheck was used to analyze five parameters of the peptide bond for each 
model (Figure 5.6): φ-ψ angles (Ramachadran Plot), peptide bond planarity (ω 
angle), bad contacts (non-bonded atoms that violate van der Waals radii), Cα 
tetrahedral distortion (ζ angle), and hydrogen bond energies (deviations from -2.0 
kcal/mol) [Kabsch and Sander 1983; Morris et al. 1992]. The analysis of these five 
parameters is dependent on the resolution of the starting structure, with less 
deviation expected/accepted for higher resolution structures. The omega torsion 
angle showed significant deviation compared to protein structures with the same 
resolution for both models. In order to address this, a stepwise energy minimization 
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was carried out. The heavy atoms, backbone, and side chain atoms were 
successively constrained and energy minimized as described in the Methods. 
However, improvement in the omega torsion angle was offset by distortion in the 
other parameters and these modifications and models were ultimately discarded 
(data not shown). The ELIC and GLIC structures were also analyzed using 
Procheck, and omega angle distortion was not observed (data not shown). 
Nevertheless, all other parameters were either better than expected or acceptable, 
compared to structural models of other proteins with the same resolution. 
 Five parameters of the side chain angles were also evaluated using Procheck 
(Figure 5.7), focusing on the Cα-Cβ (χ1) and Cβ-Cγ (χ2) angles. For both models, all 
parameters were better than expected for protein structures with the same 
resolution. The results of these experiments show that the closed and open state 
models maintain favorable amino acid stereochemistry. 
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Figure 5.4:- Collapsed agonist-binding site of homology models. (A) and (B) show the Lymnaea 
AChBP bound to carbamylcholine (PDB code: 1uv6) in green [Celie et al. 2004]. Agonist-binding 
residues from the Primary subunit are shown in blue, and those from the Complimentary subunit are 
shown in cyan. In the homology models, the agonist-binding residues point in towards the pocket that 
would be occupied by agonists and antagonists. 
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 The software program MOLE was used to visualize the ion conducting pore 
of the homology models to verify that each model accurately represented the closed 
and open state [Petrek et al. 2007]. As a control, MOLE was also used to visualize 
the ion-conducting pore of the ELIC and GLIC structures. As expected, the closed 
state model is in a non-conducting state, as a permeant ion cannot travel past a 
blockage in the region of Loop2 and the top of the pore-lining M2 helix (Figure 5.8). 
A unique observation is the presence of a constriction in the inner vestibule of the 
ligand-binding domain, at position R98 (Figure 5.8B). This constriction is not seen in 
the Lymnaea and Aplysia AChBPs, the cryo-EM images from the Torpedo nicotinic 
receptor, and subsequent homology models derived from these structures [Brejc et 
al. 2001; Hansen et al. 2004; Taly et al. 2005; Unwin 2005]. The open state model is 
in a conducting state, as a conduction pathway is evident over the entire length of 
the M2 helix (Figure 5.8D).  
 Because of the importance of the inner vestibule in ion selectivity [Hansen et 
al. 2008], we tested the hypothesis that a constriction at R98 in the closed state 
relaxes in the open state upon gating of the receptor. We hypothesized that if a 
constriction is present in the closed state, than chemical modification of introduced 
cysteines “below” the constriction would not be accessible to cysteine reagents with 
a diameter larger than that of the constriction at R98. In the open state model, the 
diameter of the vestibule is ≈ 20 Å and would no longer hinder accessibility to 
introduced cysteines located “below” position R98. Cysteine-modifying reagents with 
a diameter smaller than the constriction should be equally accessible in both the 
closed and open states (Figure 5.9).  
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Figure 5.5: Profiles 3D scores. The Profiles 3D score is plotted against the residue position for 
closed state (A) and the open state (B) models. Scores approaching zero (dashed line) and negative 
scores are interpreted as a poor fit in that region of the model. Note that the homology models 
generally follow the trendline of their respective starting structure, including regions of poor fit.  
 We chose three neutral cysteine-modifying reagents to work with; MTSBn, 
MTSEA-biotin, and DTNB. After examining the constriction in PyMOL (Figure 5.9), 
we hypothesize that Benzyl MTS should be able to pass through the approximately 
7Å x 5Å constriction, and should be equally accessible in both the closed and open 
states at residues “below” the constriction. MTSEA-biotin and DTNB are larger than 
the constriction in at least two dimensions and should not be able to pass through it. 
Therefore, we hypothesize that MTSEA-biotin and DTNB should have less access to 
introduced cysteines “below” the constriction in the closed state, and more access to 
the same position in the open state in which there is no constriction. The use of MTS 
reagents to probe the diameter and structural features of ion channels is a well 
described and validated method [del Camino and Yellen 2001].
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Figure 5.6: Model 
evaluation – Main chain. 
Procheck was used to 
evaluate the  backbone 
stereochemistry of the α7 
models in the closed (18A), 
and open states (18B). The 
evaluation depends on the 
resolution of the starting 
structures, which is 3.3Å for 
ELIC and 2.7Å for GLIC. A 
written summary of each plot 
is below each figure. Except 
for the omega torsion angle, 
all other parameters are 
either acceptable or better 
than expected for 
structures/models with the 
same resolution. 
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Figure 5.7: Model 
evaluation – Side chains. 
Procheck was used to 
evaluate the  side chain 
stereochemistry of the α7 
models in the closed (19A), 
and open states (19B). A 
written summary of each plot 
is below each figure. All 
parameters were better than 
expected for 
structures/models with the 
same resolution. 
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1
 
Figure 5.8: Outline of ion-conducting surfaces. The inner vestibule and channel pore for each structure was outlined with Voronoi mesh 
diagrams and displayed as green mesh using MOLE (Petrek 2007). Starting structures are shown in grey and α7 homology models are shown in 
white, with only three of five subunits displayed. Note that both homology models are similar to their respective starting structure. 
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 An ACh-response curve was generated before and after application of the 
cysteine-modifying reagent. To measure accessibility in the closed state, the Cys-
modifying reagents were applied individually (2mM for 60 seconds). To measure 
accessibility in the open state, the Cys-modifying reagent was applied with the 
maximal-effective dose of ACh (EC100). Accessibility of the Cys-modifying reagent 
was measured as either a right-shift or left-shift in ACh-dose response curve (ACh 
EC50), a change in the normalized peak-evoked current (Imax), and/or a change in the 
Hill coefficient . 
 Two residues were chosen as sites to introduce cysteines and validate the 
presence of a vestibular constriction. Glutamate 44 is more distal from the site of 
constriction, and is part of the transition zone that couples agonist binding to 
receptor gating. Glutamate 44 undergoes agonist and modulator-dependent 
changes in MTSEA accessibility, most likely due to changes in local electrostatic 
potential [Barron et al. 2009; McLaughlin et al. 2009]. Threonine 50 is more proximal 
to the site of constriction and has not been previously characterized. The results of 
cysteine accessibility at residue E44C and T50C on ACh-evoked currents are shown 
in Table 5.2 and Figure 5.10-5.11. MTSBn and MTSEA-biotin had a significant 
functional effect on the peak current at E44C, but there was no significant difference 
between modifications in the closed state versus open state. There was no 
significant effect of exposure to DTNB (data not shown). The same pattern was 
evident at T50C. There was a significant effect of modification with MTSBn and 
MTSEA-biotin on the ACh EC50, but there was no significant difference between 
modifications in the closed state versus the open state. MTSEA-biotin significantly 
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reduced the peak current amplitude, but again there was no significant different 
between modification in the closed versus the open state. At T50C there was no 
significant effect of exposure to DTNB (data not shown). This suggests that E44C 
and T50C are not modified by DTNB, or that there is no functional effect of 
modification. Because DTNB is the largest cysteine-modifiying reagent that was 
tested, this compound was predicted to have the greatest functional effect and was 
expected to reveal a significant change in cysteine accessibility from the closed to 
open state if a vestibular constriction was present, contrary to the observations. 
Overall these results suggest that there is no difference in closed state and open 
state modification with MTSBn and MTSEA-biotin, arguing against the presence of a 
vestibular constriction. 
 To further explore the predictive power of the homology models, in silico 
calculations of solvent accessibility and continuum electrostatics were compared 
against the rate of MTSEA modification of introduced cysteines in the ligand-binding 
domain of the α7 receptor. These physical parameters determine the reaction rate of 
a charged MTS reagent with an introduced cysteine in a protein [Karlin and Akabas 
1998]. Reaction of an MTS reagent with a thiol with deprotonated thiols (-S-) is 
upwards of 5 x 109 faster than with protonated thiols (-SH) [Bezanilla and Stefani 
1998]. Because ionization of thiol groups is suppressed in environments with a low 
dielectric constant, such as the lipid membrane in protein interior, MTS reagents 
react almost exclusively with thiols exposed to an aqueous environment [Karlin and 
Akabas 1998]. For small, charged MTS reagents, the rate of reaction also depends 
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on the local electrostatic potential. Localized areas of charge would attract or repel 
the charged MTS reagent, depending on the sign of the charge .  
 
Figure 5.9: Vestibular constriction as a gating mechanism. A constriction in the LBD at position 
R98 (blue) in the closed state model (A) of approximately 7 x 5 Å that expands to approximately 20 x 
20 Å in the open state (B). Positions distal to the constriction, towards the plasma membrane, are 
predicted to be more solvent accessible in the open state as the vestibular constriction releases. 
Accessibility at positions T50C (yellow) and E44C (red) were tested using cysteine modifiers in the 
closed and open states of the α7 receptor to verify the presence of this constriction as a gating 
mechanism. Only three subunits are shown in order to visualize the ion conduction pore. For 
reference, L247 (green) is shown as well. 
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 Solvent accessible surface area was calculated using nAccess, as described 
in Chapter 2. Two different methods exist for calculating the solvent accessible 
surface area;  the relative accessible area (RSA) measures the percentage of 
accessibility compared to a tri-amino acid peptide, and the atomic accessible area 
(ASA) measures the absolute accessibility in square angstroms [Hubbard et al. 
1991]. Both methodologies utilize the “rolling ball” model where the solvent is 
reduced to a sphere of equal radius to the starting three dimensional structure (1.4Å 
for water) and rolled along the surface of the protein (Hubbard and Thornton 1993, 
[Lee and Richards 1971; Shrake and Rupley 1973]. We compared the RSA of the 
endogenous residue to the ASA of the introduced cysteine at the same position 
(Figure 5.10). The high correlation coefficient (R2) values confirm a significant linear 
relationship between both methodologies in the closed and open state homology 
models. Either relative accessible area or atomic accessible area can be used to 
determine the solvent accessible surface area of the amino acid side chain, and 
subsequent experiments used RSA method. 
 Figure 5.14 shows the comparison of relative surface accessibility to the rate 
of reaction of MTSEA at introduced cysteines (Figure 5.12)12. Calculations of 
solvent accessibility from the closed state model were compared against MTSEA 
rates determined in the closed state (no additional ligands). Solvent accessibilities 
from the open state model were compared to MTSEA rates when an EC100 dose of 
ACh was coapplied with MTSEA. This maximally effective dose of agonist ensured 
                                                 
12
 Previously published data was used for these calculations [McLaughlin et al. 2007], except for the new data 
in Figure 5.12.  
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that the maximum number of nicotinic receptors were in the open state when 
exposed to MTSEA. There is no quantitative correlation between the solvent 
accessibility and rate of MTSEA modification in either the closed or the open state 
(Figure 5.14A). However, grouping solvent accessibility versus MTSEA modification 
by amino acid position showed a qualitative trend (Figure 5.14B). Of the 14 residues 
where MTSEA modification data was available, solvent accessibility qualitatively 
predicts the change in MTSEA rate of modification at nine residues: M37, V42, D43, 
E44, W54, W148, E172, A262, and T263. This suggests that the rate of MTSEA 
modification in the ligand-binding domain does not strictly represent a 
conformational change of the α7 nicotinic receptor. 
  
 
Figure 5.10: Neutral modification of E44C is not altered in the closed vs. open states. ACh-
response parameters were analyzed for differences between cysteine modification in the closed state 
(Cys-modifier alone) or the open state (Cys-modifier plus EC100 ACh). While a significant effect of 
modification was observed with MTSBn (A) and MTSEA-biotin (B) on peak current amplitude, there 
was no significant effect of modification in the open state (+ ACh). * =  P < 0.01, Tukey’s posthoc test, 
compared before and after MTS modification. 
 Next, we examined the contribution of continuum electrostatics to the rate of 
MTSEA modification of the α7 receptor. Continuum electrostatics calculations were 
performed using APBS as described in the Methods [Baker et al. 2001]. This 
software utilizes the Poisson-Boltzmann (PB) equation, a differential equation that 
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describes the energetic interactions of molecules in ionic solutions. An excellent 
review on the theory, derivation, and application of the Poisson-Boltzmann equation 
to structural biology is available elsewhere [Fogolari et al. 2002]. Due to limits of 
computational resources, calculations were carried out using a linearized form of the 
PB equation. Briefly, atomic coordinates are converted to units of charge and radii in 
PDB2PQR using the PARSE forcefield, as this forcefield is optimized for Poisson-
Boltzmann applications [Sitkoff et al. 1994]. The linearized PB equation overlays a 
coordinate grid over the protein structure, and the electrostatic energy at any given 
grid point depends on the ionic strength and composition, dielectric constant of 
surrounding environment, temperature, and the distance and charge of nearby 
atoms.  
 Figure 5.15 shows the results of continuum electrostatics calculations along 
the surface of the ion conduction pathway of the closed and open state α7 receptor 
homology models. For the vestibule of the ligand-binding domain, no change in 
electrostatic potential was observed between the closed and open state. The 
vestibule is composed of a portion of the A-loop, starting just past a critical agonist-
binding residue (Y92). There is no available MTS modification data from the nicotinic 
receptor family, so a comparison is not possible at this time. For the pore-lining M2 
helix, the large electronegative field in the closed state also becomes less negative 
in the open state. In the inner beta sheet and transition zone (midway along the 
vertical pore axis,) the large electronegative field in the closed state becomes less 
negative in the open state. This result is in agreement with our existing MTSEA rate 
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data, where nearly every residue tested shows a reduction in the rate of MTSEA 
modification in the open state compared to the closed state (Figure 5.15B). 
 
  
Figure 5.11: Neutral modification of T50C is not altered in the closed vs. open states. ACh-
response parameters were analyzed for differences between cysteine modification in the closed state 
(Cys-modifier alone) or the open state (Cys-modifier plus EC100 ACh). A significant effect of 
modification was observed with MTSEA-biotin on ACh EC50 peak current amplitude (A) and peak 
current amplitude (B), but was no significant effect of modification in the open state (+ ACh). MTSBn 
significantly lowered the ACh EC50 (C), but there was no difference ± ACh. * =  P < 0.01, Tukey’s 
posthoc test, compared before and after MTS modification. 
Discussion 
 In this study, we provide the first evidence that homology models of the α7 
receptor derived from bacterial Cys-loop homologs can partially predict structural 
transitions from the closed to open state.  The α7 receptor homology models were 
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validated using a combination self-validation, stereochemical, visual methods  
(Figure 5.1-5.8). Electrophysiological measurements of conformational change, as 
measured using SCAM [Akabas et al. 1992], were compared against in silico 
measurements of solvent accessible surface area and local electrostatic potential for 
the closed and open state of the α7 receptor (Figure 5.9-5.15). The strengths and 
limitations of this approach are detailed.  
  
Figure 5.12: MTSEA modification in the M2-M3 linker in the closed and open states. 
acetylcholine significantly reduces the rate of MTSEA modification at A262C, and increases the rate 
of modification at T263C (P < =0.05, n = 3). 
 
 When compared against MTSEA modification at introduced cysteines in the 
inner beta sheet and the transition zone, in silico solvent accessible surface 
qualitatively predicted the changes in accessibility with an accuracy of ≈ 66% 
(Figure 5.14B). Because electrostatic potential also influences the rate of 
modification of charged MTS reagents, it is not surprising that there is not a 
quantitative relationship between solvent accessible surface area and rates of 
* 
* 
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MTSEA modification (Figure 5.14A). Small, charged MTS reagents have been used 
extensively to study conformational changes and residue accessibility in the Cys-
loop family of ligand-gated ion channels [Reeves et al. 2001; Wilson and Karlin 
2001; Hanson and Czajkowski 2008; Barron et al. 2009]. Our results suggest that 
changes in the accessibility of introduced cysteines to charged chemical modifiers 
cannot be strictly interpreted as a structural transition or the presence of a unique 
conformation of the receptor. In the context of our previous studies of MTSEA 
accessibility in the extracellular-ligand binding domain [Barron et al. 2009; 
McLaughlin et al. 2009], the term “conformational change” should be broadened to 
include changes in electrostatic potential energy. This interpretation is supported by 
structural and single-channel data from other Cys-loop receptors where relatively 
small structural changes away from the agonist-binding site can lead to a large 
changes in ion conductivity [Cymes et al. 2005; Cymes and Grosman 2008; Hilf and 
Dutzler 2009]
  
Figure 5.13: Relative vs. Absolute Surface Accessibility. Surface accessibility was calculated as 
described in the Chapter 2. The Relative Surface Accessibility of endogenous residues is linearly 
related to the Absolute Surface Accessibility of introduced cysteines for both the closed and open 
homology models. 
  
A) α7 model - closed B) α7 model - open 
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 For charged cysteine-modifying reagents, such as cationic MTSEA, the local 
electrostatic field potential determines the accessibility of the introduced cysteine. 
The inner beta sheet and transition zone become less electronegative in the open 
state model of the α7 receptor, in agreement with our accessibility measurements 
with MTSEA (Figure 5.15A and 5.15B). There is no change in electrostatic potential 
in the inner vestibule, corresponding to the A-loop that is directly behind the agonist-
binding site.  
 Interestingly, no change in electrostatic potential was observed between the 
closed and open state homology models in the pore-lining M2 helix (Figure 5.15). 
While there is no comparable MTS rate data from the α7 nicotinic receptor, work on 
the muscle nicotinic receptor shows faster rates of MTSEA modification in the open 
state compared to the closed state and an increase in electronegativity [Pascual and 
Karlin 1998; Wilson and Karlin 2001]. One explanation is that the PB equation 
exaggerates the effects of ionic shielding and underestimates the force in systems 
with a radii smaller than the Debye length due to the continuous distribution of 
mobile ions [Moy et al. 2000]. The Debye length for our working ionic strength of 129 
mM is 8.8 Å (see Methods for calculations). For our models of the α7 receptor, the 
vestibule of the extracellular ligand-binding domain has a diameter of ≈ 20 Å and 
application of the PB equation should not suffer from shielding effects. However, the 
diameter of the transmembrane pore narrows down to ≈ 2Å at the position of the 
channel gate (-3’ to 2’). The transmembrane pores of α7 receptor and most other ion 
channels have a radii that are smaller than the Debye length calculated at 
physiological ionic strength [Hille 2001], which calls into question using the PB 
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equation and other continuum methodologies in these restricted environments. Non-
continuum methods, such as Brownian Dynamics, may be better suited because this 
approach better predicts forces in artificial and pore-like environments compared to 
the PB equation [Moy et al. 2000].  
  
1
2
3
 
Figure 5.14: MTSEA rate of modification vs. Relative Accessibility. The MTSEA rate of modification at introduced cysteines (k2, M-1sec-1) in 
the inner beta sheet, transition zone ([McLaughlin et al. 2007], Figure 5.12) plotted against the Relative Surface Accessibility (%) of the 
endogenous residue for the closed and open α7 homology models. The data is plotted independent (A) and dependent (B) on the amino acid 
residue.  “ELIC” stands for the α7 model in the closed state, and “GLIC” stands for the α7 model in the open state. 
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 Finally, we used cysteine accessibility experiments to test the hypothesis that 
the predicted constriction in the vestibule was a part of the gating mechanism. While 
both E44C and T50C were modified by MTSBn and MTSEA-biotin, there was no 
significant change in modification in the open state (+ ACh) versus the closed state 
(- ACh), arguing against our hypothesis (Figure 5.10-5.11). One possibility for this 
result is that the change in vestibular diameter from the closed to open state is 
smaller in magnitude than predicted by our homology models. In this case, the rates 
of cysteine modification would be more sensitive to subtle changes in the closed and 
open states of the α7 receptor, rather than large effects on ACh-evoked currents 
before and after maximal cysteine modification.  
 It should be noted that our in silico studies are limited to static models of the 
α7 receptor in closed and open state. Computational simulations such as molecular 
dynamics and elastic network models have provided insight into the initial and long 
timescale conformational changes associated with gating of nicotinic receptors, 
respectively. Both approaches have revealed a combination of twisting of the ligand-
binding domain and tilting of the M2 helices that allosterically converge on the 
channel gate [Hurst et al. 2005; Taly et al. 2005; Szarecka et al. 2007; Cheng et al. 
2009]. The gate is located between the -3’ and 2’ positions on the M2 helix [Wilson 
and Karlin 2001], and is preceded by a hydrophobic girdle between the 9’-17’ 
positions. Over the length of the entire M2 helix, cations are excluded but water is 
present [Beckstein and Sansom 2006; Ivanov et al. 2007]. Finally, The L9’T mutation 
is another factor to consider but our previous studies have shown that the rate of 
MTSEA modification at introduced cysteines in wildtype receptors is not significantly 
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different at receptors carrying the L9’T mutation [Barron et al. 2009]. This work 
demonstrates the limitations and pitfalls of homology models as predictors of 
receptor structure, and illustrates the importance of validation using non-
computational methods before proceeding with additional in silico studies. 
 However, several important questions about gating remain unanswered. 
Functional studies of slow onset desensitization have suggested the presence of a 
separate desensitization gate that extends from the -3’ to 9’ positions [Karlin 2002; 
Paas et al. 2005]. As all of the previously described computational simulations were 
on closed state receptor models, the conformational changes associated from the 
open state to the desensitized state are unknown. Since desensitization of nicotinic 
receptors increases proportionally to the number of binding sites [Rayes et al. 2009], 
homology models based on the heteromeric Torpedo nAChR may not accurately 
capture conformational changes associated with desensitization of the homomeric 
α7 receptor. Our validated open state model will be an excellent tool to study open to 
desensitized conformational and electrostatic changes.  
 The long-term goal of this research is to understand the conformational 
changes that underlie gating of the α7 receptor. We have presented evidence that 
closed and open state homology models of the α7 receptor are valid, and partially 
predict structural transitions associated with changes in solvent accessible surface 
area and local electrostatic potential. However, a vestibular constriction in the closed 
state could not be verified using cysteine modification, and illustrating the pitfalls of 
using only computational methodology to study gating mechanisms of ion channel 
receptors.
  
1
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Figure 5.15: Reduction of electronegativity better predicts conformational changes in the LBD. Calculations were carried out using APBS, 
as described in the Chapter 2. Units are in kT/e [(Boltzmann’s Constant * Temperature)/Elementary Charge], with the scale bars shown below the 
protein model. Only three of the five subunits for each receptor is shown, in order to visualize the ion-conducting surface. The change to a more 
positive electrostatic potential from the closed to open state in the inner beta sheet region agrees with previously published data from our lab 
(McLaughlin 2007, Barron 2009).  
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Table 5.1 - Summary of ACh responses before cysteine modification 
 
Mutant cysteine Modifier ACh EC50 (µM) Hill Coefficient Imax (µA)  n 
E44C MTSBn 7.74 ± 1.46 2.33 ± 0.22 5.66 ± 0.94 3 
 MTSBn + ACh 8.57 ± 0.69 2.15 ± 0.22 5.37 ± 2.21 3 
 MTSEA-biotin 9.13 ± 1.51 2.74 ± 0.35 7.10 ± 1.92 3 
 MTSEA-biotin + ACh 8.63 ± 1.41 3.15 ± 0.79 6.79 ± 1.15 4 
 DTNB 6.70 ± 0.92 2.97 ± 0.26 5.89 ± 2.11 3 
 DTNB + ACh 7.71 ± 0.34 2.46 ± 0.18 8.45 ± 2.13 3 
            
E44C Average 9.29 ± 1.13 2.51 ± 0.21 6.59 ± 0.65 19 
            
T50C† MTSBn 5.90 ± 0.32 3.03 ± 0.21 2.08 ± 1.34 3 
 MTSBn + ACh 6.18 ± 0.64 2.99 ± 0.53 2.95 ± 2.05 3 
 MTSEA-biotin 6.35 ± 0.33 3.17 ± 0.31 1.47 ± 1.19 3 
 MTSEA-biotin + ACh 6.51 ± 0.32 3.55 ± 0.52 1.76 ± 1.45 3 
 DTNB 5.98 ± 0.53 3.14 ± 0.85 3.61 ± 0.75 3 
 DTNB + ACh 6.56 ± 0.40 2.86 ± 0.45 1.73 ± 1.46 3 
            
T50C† Average 2.27 ± 0.52 3.12 ± 0.19 2.27 ± 0.52 18 
 
† = denotes co-expression with human RIC-3 (see Chapter 2). 
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Table 5.2 - Summary of ACh responses after cysteine modification 
 
Mutant cysteine Modifier ACh EC50 (µM)  Hill Coefficient Change in Peak Current+    n 
E44C MTSBn 18.60 ± 7.83  1.74 ± 0.22 0.16 ± 0.01 * 3 
 MTSBn + ACh 7.96 ± 1.16  2.68 ± 0.84 0.12 ± 0.04 * 3 
 MTSEA-biotin 5.84 ± 0.91  2.33 ± 0.38 0.80 ± 0.02 * 3 
 MTSEA-biotin + ACh 5.94 ± 0.79  2.31 ± 0.12 0.71 ± 0.06 * 4 
 DTNB 6.91 ± 0.65  2.81 ± 0.09 0.97 ± 0.03  3 
 DTNB + ACh 7.22 ± 0.35  2.65 ± 0.19 1.02 ± 0.05  3 
              
T50C† MTSBn 3.09 ± 0.34 * 3.02 ± 0.89 1.03 ± 0.15  3 
 MTSBn + ACh 3.27 ± 0.41 * 3.10 ± 0.96 0.99 ± 0.10  3 
 MTSEA-biotin 13.17 ± 2.24 * 3.08 ± 0.51 0.71 ± 0.03 * 3 
 MTSEA-biotin + ACh 10.14 ± 1.90 * 3.03 ± 0.18 0.73 ± 0.04 * 3 
 DTNB 7.45 ± 1.47  2.40 ± 0.48 1.10 ± 0.11  3 
 DTNB + ACh 6.64 ± 0.71  3.10 ± 0.60 0.93 ± 0.05  3 
 
 
+ = The Change in Peak current was calculated as the Imax after cysteine modification divided by the Imax before 
       cysteine modification 
* = P < 0.01, before cysteine modification within the same treatment group.  
† = denotes co-expression with human RIC-3 (see Chapter 2).
  
 
 
CHAPTER 6 
 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
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 The goal of this work was to define the molecular mechanisms of positive 
allosteric modulation of the α7 nicotinic acetylcholine receptor. The development of 
new agonists and PAMs targeting the α7 and other nAChRs is an area of active of 
research because of their unique neurophysiology and connection to a wide variety 
of neurological disorders [Gotti and Clementi 2004]. In particular, PAMs may have a 
unique therapeutic potential because of the requirement of agonists to enhance 
channel current. In the synaptic cleft, cholinergic neurotransmission is tightly 
controlled by the rapid degradation of ACh by acetylcholinesterase and the recovery 
of choline by the high-affinity choline transporter [Amenta and Tayebati 2008]. PAMs 
of the α7 nAChR (Type I or Type II) should preserve the tight temporal timing of 
cholinergic neurotransmission because these compounds (with the notable 
exception of galanthamine; [Samochocki et al. 2003]) do not alter the kinetics of ACh 
degradation or choline transport.  
 In order to elucidate the mechanisms of allostery, we used SCAM to probe to 
conformation transitions of the α7 receptor in the closed, open, and “modulated” 
states. We have demonstrated that two positive allosteric modulators (Ba2+ and 
PNU-120596) cause similar changes in the rate of cysteine accessibility as of the 
agonist acetylcholine in the agonist-binding domain, in spite of large differences in 
chemical structure and effects on macroscopic desensitization.  As a complimentary 
technique, we also developed homology models of the α7 receptor from the 
structures of bacterial Cys-loop receptors to study receptor gating. We found that 
electrostatics are a better predictor of cysteine accessibility in the LBD than physical 
rearrangements. The significance of these findings, future studies and additional 
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methods to elucidate the mechanisms of positive allosteric modulation and receptor 
gating will be discussed below.  
 
Agonists and PAMS cause similar conformational changes in the LBD 
 In order to investigate mechanisms of allostery of the nAChRs, we utilized the 
Substituted cysteine Accessibility Method (SCAM). This method has several 
advantages with respect to ion channels, such as using changes in peak current 
amplitude as an instant readout of cysteine modification, and is a well-established 
technique to study mechanisms of gating and surface accessibility in ion channels. 
Because of the infinite combinations of possible sites to mutate to a cysteine and 
cysteine-modifying reagents to test, our experiments were designed to test 
representative allosteric modulators and sites of interest with our most sensitive 
cysteine-modifying reagent, MTSEA. We chose two positive allosteric modulators, 
Ba2+ and PNU-120596, because of their different size and chemistry, and because 
of their different effects on macroscopic desensitization. Barium and other 
permeable divalent cations to do not alter macroscopic desensitization (making them 
Type I modulators) [Eddins et al. 2002a], whereas PNU-120596 eliminates receptor 
desensitization (Type II) [Gronlien et al. 2007]. We chose 2-3 residues each from 
different regions of the LBD; the agonist-binding site, the inner beta sheet, and the 
transition zone (Figure 1.1, 3.1). Other possible and published experimental designs 
include complete sampling of a sub region with a single cysteine-modifying reagent 
[Kloda and Czajkowski 2007], studying fewer residues with a larger number of 
pharmacological compounds and cysteine-modifying reagents [Chang and Weiss 
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2002], or studying the desensitized state in addition to the closed and open states of 
the receptor [Wilson and Karlin 2001]. Our experimental design is a useful template 
for the initial characterization of a new or untested compound and understanding the 
broader mechanisms of allostery for the entire protein. 
 Using SCAM, we determined that Ba2+ and PNU-120596 cause similar but 
non-identical changes in the rate of cysteine modification with MTSEA in the 
extracellular agonist-binding domain of the α7 receptor, compared to acetylcholine.  
Whether the change in cysteine accessibility is reflective of a structural transition or 
a change in the local electrostatic potential, it appears that PAMs induce some of the 
critical rearrangements associated with activation as agonists.  Determining if these 
conformational changes are associated with an increase in the binding affinity for 
agonists, or an increase in channel gating is an important area for future studies. 
Radioligand binding experiments with labeled competitive antagonist in the presence 
of positive allosteric modulators could be used to assay changes in binding affinity at 
the agonist-binding site. A decrease in the dissociation constant (Ki) for a 
competitive antagonist or agonist in the presence of a positive allosteric modulator 
would provide evidence of a direct interaction between the agonist-binding site and 
putative binding sites for permeable divalent cations and PNU-120596 [Galzi et al. 
1996; Bertrand et al. 2008; Young et al. 2008]. Work on the GABAA receptors 
suggests that benzodiazepines and agonists cause a reciprocal increase the binding 
affinity at their respective binding sites, [Olsen and Snowman 1982; Rogers et al. 
1994], but pentobarbital does not induce conformational changes at the 
benzodiazepine binding site [Sharkey and Czajkowski 2008]. This suggests that 
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coupling between different allosteric sites to the orthosteric site(s) may not be 
conserved. 
 In addition, single channel recordings could be used to study the role of both 
increased channel gating and increased agonist binding affinity as a mechanism for 
positive allosteric modulators. The limited single-channel data from PNU-120596 on 
α7 receptors suggests that this compound increases the mean open time [Hurst et 
al. 2005]. However, because PNU-120596 does not evoke currents on wildtype α7 
receptors in the absence of agonists, it is unknown if this compound simply 
enhances the kinetic reaction scheme employed by agonists (Figure 1.2), or utilizes 
an alternative conformational pathway. This body of work identified a pair of 
mutations that convert PNU-120596 to a full agonist (W148C-L247T; Figure 3.7A), 
which could be used to directly study the effect of PNU-120596 on single channels. 
Another approach would be to study PNU-evoked currents on a mutant receptor that 
has a high spontaneous open probability. In both experiments, PNU-evoked currents 
would be studied as a surrogate for allosteric modulation, but would need to be well 
controlled to ensure that introduction of these mutations preserves the 
pharmacological profile of this compound. The equivalent mutations in the muscle 
nAChR that increase spontaneous opening have not yet been studied in the α7 
receptor [Purohit and Auerbach 2009]. However, we have studied the W148C-L247T 
mutant and found that the PNU EC50 value and Type II modulation profile were not 
affected (Figure 3.2, 3.7A), which would make this mutant receptor a suitable model 
for single-channel recordings.  
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Evidence against the putative Ca2+ binding site 
 One particular challenge in studying allosteric modulators of ion channels is 
the complex relationship between macroscopic half-maximal excitatory dose (EC50), 
binding affinity, and channel gating.  In short, the EC50 value for an agonist or a 
positive allosteric modulator is an aggregate of the binding affinity of the compound, 
and the ability of that binding energy to induce and/or enhance the conformational 
changes from the closed to open states [Jackson 1989; Colquhoun 1998]. For the α7 
nicotinic receptor, the EC50 values of several allosteric modulators (including PNU-
120596) are in the low micromolar to low millimolar range [Gronlien et al. 2007; 
Timmermann et al. 2007], which likely translates into binding affinities that are too 
low to be directly measured using radioligand binding assays. Our results support 
this, as direct binding of [3H]PNU-120596 to α7 receptor-enriched membranes did 
not yield any specific binding (data not shown). Therefore, the study of allosteric 
modulators has been limited to site-directed mutagenesis to discover important 
residues. 
 The putative permeable divalent cation binding site was initially characterized 
using site-directed mutagenesis of glutamates in the LBD and luminescent 
resonance energy transfer of Tb3+ binding to α7 receptor peptides [Galzi et al. 1996]. 
While E44 and E172 play an important role in allosteric modulation by divalent 
cations, there are several caveats concluding these residues constitute a binding 
site. First, a short α7 receptor peptide is not likely to have the same three-
dimensional structure as the full length, membrane-embedded receptor. Secondly, 
the distances between the conserved glutamates in α7 receptor homology models 
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are too great to coordinate a calcium ion [Le Novere et al. 2002; Harding 2004; Taly 
et al. 2005]. To test the existing hypothesis of a Ca2+ binding site at E44 and E172, 
we combined a cysteine mutation that is sensitive to allosteric transitions by Ba2+ 
(M40C, Figure 4.4) and a charge neutralization mutation in the putative binding site 
(E172Q) that eliminates allosteric modulation by Ca2+ [Galzi et al. 1996]. If E172 is 
part of a Ca2+ binding site, then the charge neutralization mutation should also 
eliminate structural transitions measured at a reporter residue.  Because Ba2+ 
induced conformational changes at M40C with the addition of the E172Q mutation 
(Figure 4.6), we conclude that E172 is not part of a divalent cation binding site.  
 Given our results, the location of the divalent cation-binding site remains an 
open question. Previous work from our lab suggests that the permeable divalent 
cation binding site is in the LBD of the α7 receptor [Eddins et al. 2002a; Eddins et al. 
2002b], and one likely candidate would be the agonist-binding site. Cations can 
interact at  the agonist-binding site, as monovalent cations act as low affinity, 
competitive antagonists in muscle-type nAChRs [Akk and Auerbach 1996]. In α7 
receptors, divalent cations could act as PAMs at unoccupied agonist-binding sites, 
similar to benzodiazepines and GABAA receptors. Other possible divalent cation 
sites were identified in the structure of the AChBP [Brejc et al. 2001], but have not 
yet been tested. 
 
Methodologies to study low-affinity sites 
While mutagenesis studies are limited in their ability to conclusively identify a 
binding site, several alternative techniques exist to study low-affinity binding sites on 
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membrane receptors. One alternative method to determine the divalent cation site 
would be the 45Ca2+ overlay [Bian et al. 2001]. Briefly, overexpressed α7 receptor 
would be separated by SDS-PAGE, transferred to polyvinyl fluoride membranes, 
exposed to 45CaCl2 and visualized with autoradiography. The relative amount of 
45Ca2+ binding could be compared between wildtype and receptors mutated at 
putative binding sites. While this technique cannot be used to calculate a binding 
affinity, changes in 45Ca2+ binding would provide evidence for or against the 
importance of those locations13. Another technique that could be used to calculate a 
binding affinity for Ba2+, PNU-120596, and other low-affinity compounds would be 
isothermal titration calorimetry [Turnbull and Daranas 2003]. In brief, changes in the 
enthalpy of detergent-solubilized receptor caused by the binding of compounds can 
be used to calculate association and dissociation constants. Photoaffinity labeling 
studies can be used to independently determine compound binding sites without the 
requirement for site-directed mutagenesis [Nirthanan et al. 2008]. Finally, techniques 
such as diffusion-enhanced luminescent energy transfer from Tb3+ to α7 receptor 
agonists and PAMs could be used to directly calculate changes electrostatic 
potential as well as the amount of energy transferred to the receptor from the 
modulating compound [Meltzer et al. 2006a; Meltzer et al. 2006b; Meltzer et al. 
2006c].  
The common thread in the above-mentioned techniques is that they all 
require large amounts of highly purified protein. Historically, the Torpedo marmorata 
                                                 
13
 This technique has been successfully used to identify high-affinity calcium binding sites, such as the EF-hand 
motif found in calmodulin [Bian et al. 2001]. This approach could not identify a calcium-binding site at the 
interface between receptor subunits, because the protein samples are denatured prior to running on an SDS-
PAGE gel.  
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nAChR has been the receptor of choice because large amounts of receptor can be 
purified from the electric organ [Nirthanan et al. 2005]. In contrast, the ability to 
overexpress and purify large quantities of full-length α7 receptor has long been a 
technical challenge due in part to the low surface expression of this receptor from in 
vitro systems [Fischer et al. 2001]. However, two technical advances in the last 
seven years may facilitate overexpression of large quantities of the α7 receptor. 
First, the chaperone protein RIC-3 is required for proper cycling of the α7 receptor to 
the plasma membrane in eukaryotes. [Halevi et al. 2002; Lansdell et al. 2005; 
Castelan et al. 2008]. Increasing the cell surface expression of the α7 nAChR would 
allow more protein to be purified in subsequent experiments. Second, the 
standardization of vectors and methodology for overexpression and purification of 
membrane receptors from Saccharomyces cerevisiae (Baker’s Yeast) has been 
outlined in thorough detail, and is an attractive model system to ensure proper 
receptor folding and retention of post-translational modifications [Newstead et al. 
2007; Drew et al. 2008]. Coexpression of RIC-3 and the α7 nicotinic receptor in S. 
cerevisiae and subsequent purification by GFP and Ni2+ affinity columns would be an 
active area of future work as a prerequisite to additional biophysical and biochemical 
studies of allosteric modulation.  
   
Electrostatic compensation as a unifying model for receptor gating 
 A broader goal of this work is to elucidate the gating mechanism of the Cys-
loop receptor family, and the isomerization from an ion-impermeable to an ion-
permeable conformational state. Since the initial cryo-EM characterization of the 
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Torpedo nAChR by Unwin and colleagues [Toyoshima and Unwin 1988; Unwin 
1993; Unwin 1995], multiple and sometimes conflicting mechanisms for receptor 
gating have been proposed. The initial hypothesis of a rigid-body rotation of 
individual subunits [Miyazawa et al. 2003] has evolved into the quaternary twist 
hypothesis, which incorporates both rotational and tilting motions [Taly et al. 2005; 
Taly et al. 2006]. Subtle tilting of the transmembrane α-helices is supported by 
higher-resolution x-ray crystallography of bacterial Cys-loop receptors [Hilf and 
Dutzler 2008; Bocquet et al. 2009; Hilf and Dutzler 2009]. Importantly, relatively 
small conformational changes in the TMD as a gating mechanism (such as helix 
tilting) are also supported by protonization of titratable residues [Cymes et al. 2005; 
Cymes and Grosman 2008]. Experimental confirmation of these proposed 
mechanisms is crucial to determining the true gating mechanisms of the Cys-loop 
receptor family. 
 In order to explore the role of the LBD in gating of the α7 receptor, we 
developed homology models in the closed and open states of the bacterial Cys-loop 
receptor structures and compared our existing MTSEA accessibility data 
[McLaughlin et al. 2007]. In particular, we assayed changes in structure (solvent 
accessibility) and electrostatics in closed vs. the open state models. While individual 
residues are predicted to undergo large structural transitions (Figure 5.14), changes 
in electrostatics in the LBD are a better predictor of the closed to open isomerization 
(Figure 5.15). This conclusion is also supported by structural observations from the 
closed and open state models, where the large diameter of the extracellular 
vestibule remains the same [Taly et al. 2009]. 
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 In particular, we observed decrease in the electronegative surface area in the 
inner beta sheet and transition zone. This result seems counterintuitive, as an 
increase in electronegative surface area would likely attract a greater number of 
cations and increase cation flux through the ion-permeation pathway of the receptor. 
So how can we reconcile this observation? First, we will assume that a large 
macromolecule such as the α7 nAChR maintains a constant net charge under 
physiological pH and ionic strength. Because only a small transference of charge is 
necessary to alter cellular membrane potential, this is a reasonable assumption 
[Hille 2001]. Second, we will assume that structural transitions precede changes in 
electrostatics. With these assumptions in mind, we hypothesize that any change in 
local electrostatic potential during the closed-open gating transition would be 
compensated by an opposite change in potential in other regions of the receptor. 
In other words, if the electrostatic potential decreases in one region it would have to 
increase in a different region of the receptor in order to maintain a constant net 
charge. For an ion channel, the most likely candidate site for electrostatic 
compensation would be the TMD, where the energy barrier to ion permeation is the 
highest. This hypothesis is attractive as it reconciles our observations using MTSEA 
modification and electrostatic modeling with the existing theories on ion permeation 
through the Cys-loop receptor, including electric focusing by charged rings along the 
ion permeation path and the hydrophobic girdle in the M2 helix. A decrease in the 
electrostatic potential (less negative) in the LBD could be compensated by an 
increase in electrostatic potential (more negative) in the TMD, which would further 
lower the energy barrier to ion translocation in the open state.  
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 MTS analysis of electrostatics in the M2 helix of muscle nAChRs supports our 
“electrostatic compensation” hypothesis, as the electrostatic potential dramatically 
increases by -75 to -125 mV from the closed to open states. [Pascual and Karlin 
1998]. To further test our hypothesis, we will want to be able to directly compare and 
quantify changes in electrostatic potential. Cysteine modification with either a neutral 
or a positively charged compound, in addition to our existing MTSEA data, can be 
used to calculate changes in electrostatic potential. While we have found the LBD to 
be insensitive to cationic cysteine modifiers (Figure 3.11), small hydrophobic 
modifiers such as MTSBn or MMTS would likely work, and our results of E44C 
modification with MTSBn are encouraging (Figure 5.10). Therefore, one important 
future direction would be to measure rates of MTSBn modification at our existing 
cysteine mutants in the agonist-binding site, inner beta sheet, transition zone, and 
M1-M2 linker (Table 3.2, Figure 5.12) and calculate changes in electrostatic 
potential in the open and modulated states. An added advantage to adding a small, 
hydrophobic MTS reagent to our repertoire is that these reagents will allow us to 
better distinguish between conformational changes and changes in electrostatics. 
 Another line of future experiments to test our “electrostatic compensation” 
model would be to investigate agonist- and PAM-induced structural transitions in the 
M2 helix using SCAM. While some might argue that pursuing these experiments in 
the α7 receptor is too similar to the work done in the muscle nAChR [Pascual and 
Karlin 1998; Wilson and Karlin 2001], there are several compelling reasons to 
pursue these experiments. Alpha7 nAChRs are different from muscle nAChRs with 
respect to Ca2+ permeability and rate of desensitization, so there is no a priori 
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reason to assume that agonist-induced structural transitions of α7 receptor will be 
identical to those of the muscle nAChR. Secondly, the real novelty of these 
experiments would be to explore PAM-induced structural transitions, and comparing 
these results to parallel experiments examining agonist-induced changes. Because 
PAMs do not directly gate the α7 receptor, we would predict a divergence in 
structural transitions between PAMs and agonists somewhere in the M2 helix. 
 The findings presented in this dissertation indicate that positive allosteric 
modulators and agonists share a conserved gating mechanism in the extracellular 
ligand-binding domain of the α7 nicotinic receptor.  Further analysis using high-
resolution homology models showed that a change in electrostatics between the 
closed and open states is primary mechanism associated with receptor gating. 
These findings advance our understanding of allostery and receptor gating, and 
could enhance the drug discovery process.  Future studies will focus on the 
molecular mechanisms associated from the open to desensitized transition using the 
open state model and cysteine accessibility, and modulation of these processes by 
positive allosteric modulators.  
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